

Curriculum Vitae

Narendranath Epperla MD, MS

Assistant Professor
Department of Medicine
Division of Hematology

OFFICE ADDRESS

The Ohio State University Wexner Medical Center
A346 Starling Loving Hall, 320 W 10th Ave,
Columbus, OH, 43210
Email: Narendranath.Epperla@osumc.edu

GRADUATE EDUCATION

09/2001 – 08/2007 MBBS, Kamineni Institute of Medical Sciences, Narketpally, India
08/2015 – 05/2017 M.S., Clinical and Translational Science Institute of Southeast Wisconsin, Medical College of Wisconsin, Milwaukee, WI

POSTGRADUATION TRAINING AND FELLOWSHIP APPOINTMENTS

09/2007 – 04/2008 Research Assistant at Niloufer Hospital, Hyderabad, India
04/2008 – 01/2009 Chief Medical Officer at Tirumala Multispecialty Hospital, Hyderabad, India
02/2009 – 03/2010 Clinical Trainee at various hospitals in the USA
07/2010 – 06/2011 Intern, Internal Medicine, Marshfield Clinic/Ministry Saint Joseph's Hospital
Marshfield Clinic, 1000 N Oak Ave, Marshfield, WI
07/2011 – 06/2013 Resident, Internal Medicine, Marshfield Clinic/Ministry Saint Joseph's Hospital
Marshfield Clinic, 1000 N Oak Ave, Marshfield, WI
07/2012 – 06/2013 Chief Resident, Internal Medicine, Marshfield Clinic/ Ministry Saint Joseph's Hospital
Marshfield Clinic, 1000 N Oak Ave, Marshfield, WI
07/2014 – 06/2017 Fellow, Hematology/Oncology, Medical College of Wisconsin
9200 W Wisconsin Ave, Milwaukee, WI

FACULTY APPOINTMENTS

07/2013 – 06/2014 Assistant Professor, Dept. of Internal Medicine, Marshfield Clinic, 1000 N Oak Ave,
Marshfield, WI
07/2017 – Present Assistant Professor, Dept. of Medicine, Division of Hematology, The Ohio State
University, 320 W 10th Ave, Columbus, OH

SPECIALTY BOARDS AND CERTIFICATIONS

Internal Medicine: 08/2013, Exp. Date 08/2023

Hematology: 12/2017, Exp. Date 12/2027

Medical Oncology: 12/2017, Exp. Date 12/2027

Ohio State License: Exp. Date 01/01/2023

DEA Registration: Exp. Date 08/31/2023

AWARDS AND HONORS

- 04/2004 Gold Medal in Pharmacology (MS2)
- 04/2004 Gold Medal for Highest Aggregate in II MBBS (MS2)
- 01/2005 Gold Medal for Oral Research Presentation, 11th State Conference of Indian Association of Preventive & Social Medicine and Indian Public Health Association (MS3), Vishakhapatnam, India
- 01/2005 Second place, Interschool Preventive & Social Medicine Jeopardy (MS3), Vishakhapatnam, India
- 08/2005 Second place, Interschool Pediatrics Jeopardy (MS4), Indian Academy of Pediatrics, Hyderabad, India
- 09/2012 Second place, Medical Jeopardy, ACP State Summit, WI Dells, WI
- 09/2012 Moderated Resident Oral Presentation Session, Society for General Internal Medicine (SGIM), Chicago
- 05/2013 Sixth Annual Nikolai Award for Outstanding Resident Research, Marshfield Clinic, Marshfield, WI
- 06/2013 Outstanding Resident of the Year Award, Marshfield Clinic, Marshfield, WI
- 10/2015 Hematology Fellows Consortium (HFC) Trainee Grant
- 04/2016 Hemostasis and Thrombosis Research Society (HTRS) Trainee Grant
- 06/2016 American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation Merit Award
- 06/2016 Medical College of Wisconsin Affiliated Hospitals (MCWAH) Research Award
- 07/2016 Donald J Schuenke Cancer Fellowship Award 2016-2017 providing stipend support and assistance for research activities to fellow showing excellence in educational, clinical and research activity; Source: Froedtert Hospital Foundation
- 12/2016 American Society for Blood and Marrow Transplantation (ASBMT) Travel Grant
- 04/2017 CSCTR/MWAFMR Combined Annual Meeting Travel Grant
- 07/2017 Scholar, Clinical Research Training Course (CRTC), ASBMT, Charlotte, North Carolina.
- 08/2019 Scholar, Clinical Research Training Institute (CRTI), ASH, La Jolla, CA.
- 12/2019 Program Chair, OnLive State of the Science Summit, Columbus, OH.
- 04/2020 Judge, OSU College of Medicine Trainee Research Day, Columbus, OH.
- 06/2020 DSRP grant reviewer, Columbus, OH.
- 12/2020 Moderator, Session 905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Outcomes Research Real World Data Healthcare Disparities at the 62nd ASH annual meeting, 2020.
- 12/2020 Program Chair, OnLive Institutional Perspectives in Cancer and State of the Science Summit, Leukemia/Lymphoma, Columbus, OH.

MEMBERSHIP IN HONORARY AND PROFESSIONAL SOCIETIES

- 2007 - Present Medical Council of India (Member)
- 2009 - Present American Medical Association (Member)
- 2010 – Present Wisconsin Medical Society (Member)
- 2013 – Present American Society of Hematology (Member)

2014 – Present	American Society of Clinical Oncology (Member)
2016 – Present	American Society for Blood and Marrow Transplantation (Member)
2018 – Present	American Association for Cancer Research (Member)
2019 – Present	American College of Physicians (Member)

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS

Editorial Board

2015 – Present	Austin Journal of Medical Oncology (IF=1.2)
2015 – Present	Annals of Hematology and Oncology (IF=2.1)
2018 – Present	Frontiers in Oncology (IF=4.84)

Journal Review

2015 – Present	British Journal of Radiology
2016 – Present	Drug Design, Development and Therapy
2016 – Present	Journal of American Medical Association (JAMA) Oncology
2016 – Present	New England Journal of Medicine
2017 – Present	Bone Marrow Transplantation
2018 – Present	Leukemia Research
2018 – Present	Cancer Management and Research
2018 – Present	Haematologica
2018 – Present	Blood
2019 – Present	Biology of Blood and Marrow Transplantation
2019 – Present	American Journal of Hematology
2019 – Present	Blood Advances
2019 – Present	Leukemia and Lymphoma
2019 – Present	British Journal of Haematology
2019 – Present	European Journal of Haematology
2019 – Present	Expert Review of Hematology
2020 – Present	Annals of Internal Medicine
2020 – Present	Biomarker Research
2020 – Present	Cancers
2020 – Present	Journal of Hematology and Oncology
2020 – Present	Clinical and Translational Medicine
2020 – Present	Theranostics
2020 – Present	Critical Reviews in Oncology/Hematology
2020 – Present	Cancer Medicine
2020 – Present	Journal of Personalized Medicine
2020 – Present	Cancer Control
2020 – Present	JCO Precision Oncology

LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS

08/2010 – 06/2013	Member, American College of Physicians (ACP) council, ACP state chapter, WI
06/2012 – 06/2013	Resident Representative for the state of WI, Leadership meeting for American College of Physicians (ACP), Washington DC
04/2018 – Present	Scientific reviewer, Clinical Scientific Review Committee, The Ohio State University
07/2018 – Present	Learning Communities Leader, The Ohio State University
11/2019 – Present	Member, Biomedical Sciences Institutional Review Board (IRB), The Ohio State University

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS

2016 - 2017	Member, American Medical Association, Resident-Fellows section (AMA-RFS) committee on scientific research
2016 - Present	Member, Hodgkin and NHL working committee, CIBMTR
2016 - Present	Member, Acute and Chronic Leukemia working committee, CIBMTR
2016 - Present	Member, Plasma cell disorders working committee, CIBMTR

RESEARCH GRANTS/AWARDS/CONTRACTS

Title:	Association between blood glucose level and outcomes in patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease
Source:	Marshfield Clinic Research Foundation
Role:	Co-Investigator
Dates:	07/2010 – 06/2012

Title:	Impact of Intervention on Cardiovascular Outcomes in Symptomatic Subclavian Artery Stenosis
Source:	Marshfield Clinic Research Foundation
Role:	Principal Investigator
Dates:	08/2012 – 06/2014

Title:	Development of a Novel Scoring System for the Diagnosis and Disease monitoring of Classic and Variant Hairy Cell Leukemia
Source:	Hairy Cell Leukemia Foundation
Role:	Co-Investigator
Dates:	12/2018 – 12/2020

CLINICAL TRIALS

Title:	A phase II, Open-Label Study of Propylene Glycol-Free Melphalan HCl (EVOMELA) in combination with Fludarabine and Total Body Irradiation based Reduced Intensity Conditioning for Haploidentical Transplantation (NCT03159702)
Source:	Spectrum Pharmaceuticals
Role:	Co-Investigator (wrote the protocol as fellow)

Dates: 12/2017 - Ongoing

Title: QUILT-3.002: ALT-803 in Patients with Relapsed/Refractory iNHL in Conjunction with Rituximab (NCT02384954)

Source: Altor BioScience

Role: Principal Investigator

Dates: 04/2018 – 01/2021

Title: Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants with Diffuse Large B-cell Lymphoma (NCT03656835)

Source: OSUCC

Role: Principal Investigator

Dates: 09/2018 – Ongoing

Title: A Phase II Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL) (NCT03105336)

Source: Kite Pharma, Inc

Role: Principal Investigator

Dates: 11/2020 – Ongoing

EDUCATIONAL ACTIVITIES

Academic Advising and Mentorship

Time period as mentee	Name	Degree(s)	Position as mentee	Project	Capacity of mentoring*	Current position (if known)
2013-2014	Barrett Parker Wagner		Third-year Medical Student	Published a paper on amelanotic metastatic malignant melanoma in a peer-reviewed journal	Clinical and Research Mentorship	University of Wisconsin School of Medicine and Public Health
2014-2015	Apoorva Jayarangaiah	MD	Second-year IM Resident	- Published a paper on a complex case of neuromyelitis optica spectrum disorders in a peer-reviewed journal - Oral presentation on "Epstein syndrome" at national American College of Physicians (ACP) that won the award for the best clinical vignette, 5/2016 at Washington DC	Clinical and Research Mentorship	Marshfield Clinic
2015-2016	Christopher Strouse	MD	Third-year IM Resident	Published two papers, one on Gemcitabine-associated pseudo-cellulitis, and the other on autoimmune hemolytic anemia treated with Hemopure in peer-reviewed journals	Clinical and Research Mentorship	Medical College of Wisconsin
2015-2016	Katherine Hemauer	MD	Second-year IM Resident	Worked on 3 projects: 1. Congenital TTP related to novel mutation in ADAMTS13 gene and management during pregnancy 2. Extracavitary PEL associated with HLH 3. Post-transplant drug associated TMA	Clinical and Research Mentorship	Medical College of Wisconsin
2016	Adam Levin	MD	Second-year IM Resident	Poster presentation on "Role of Curcumin in the treatment of pancreatic cancer" at regional ACP (WI ACP state chapter)	Clinical and Research Mentorship	Medical College of Wisconsin
2016-2017	Lindsay Hoogenboom	MD	Second-year IM Resident	Poster presentation on "A Ray of Hope in Catastrophe" at the International AMA-RFS symposium	Research Mentorship	Medical College of Wisconsin
2016-2017	Ariel Kleman	MD	Second-year IM Resident	Submitted abstract for 12th HHT international Scientific Conference – "Retreatment vs maintenance strategy of systemic bevacizumab for Hereditary Haemorrhagic Telangiectasia: Which is better?"	Clinical and Research Mentorship	Medical College of Wisconsin
2017-	John Vaughn	MD	Hospitalist	Worked on 2 projects:	Clinical and	The Ohio State

2018				1. Follicular lymphoma grade 3A study, 2. Impact of post autologous hematopoietic cell transplantation outcomes in classical Hodgkin lymphoma and DLBCL	Research Mentorship	University
2018-Present	Alexandria Lenyo		Undergraduate	Worked on post allogeneic transplantation outcomes in Richter's syndrome patients.	Research Mentorship	The Ohio State University
2018-Present	Joshua Gordon	MD	Second-year IM Resident	Submitted 2 abstracts to National ACP 2018, one related to excessive cinnamon intake and agranulocytosis and the other, excess green tea consumption and cold agglutinin autoimmune hemolytic anemia in a patient with Hairy cell leukemia	Clinical and Research Mentorship	The Ohio State University
2018 - Present	Abdullah Khan	MD	Junior Faculty	Post allo-HCT relapse outcomes in MM	Peer Mentor	The Ohio State University
2019 - Present	Sayan Mullick Chowdhury	PhD	Third- year Medical Student	- SRS and R2 in relapsed CNS lymphomas* - Evaluating the outcomes of patients with WM with osseous involvement *Received trainee grant for CSCTR meeting and received featured new investigator award.	Research Mentorship	The Ohio State University
2019 - Present	John Vaughn	MD	Fellow	- Racial and healthcare Disparity Research - Presented 4 studies at ASH annual meeting 2020; 3 posters and 1 oral	Research Mentorship	Weill Cornell University
2019 - Present	Walter Hanel	MD	Fellow/ Instructor	- Studying the role of CNS ppx in double expressor DLBCL patients - Review on mantle cell lymphoma patients study	Research Mentorship	The Ohio State University
2020-2021	Muhammad Salman Faisal	MD	BMT Fellow	Time-trend analysis in Hodgkin lymphoma patients undergoing allogeneic transplantation	Research Mentorship	The Ohio State University

Invited Presentations**International**

02/2021 "What is erythropoiesis", International medical education project – Destination Medicine

National

08/2016 "Mantle cell lymphoma – *where are we in 2016*", Marshfield Clinic, Marshfield, WI, 54449

10/2016 "360 degree view of lymphoma – Novel agents, Surveillance, and Transplant" – The Ohio State University, Columbus, OH, 43210

09/2017 "Current Updates in Low grade Lymphomas", OncLive State of the Science Summit, Columbus, OH, 43210

07/2019 "The Evolving Therapeutic Landscape of Mantle cell lymphoma – The Past, Present and Future", Guest lecture at University of New Mexico, Albuquerque, NM, 87131

12/2019 "Updates in Hodgkin and Non-Hodgkin Lymphomas", OncLive State of the Science Summit, Columbus, OH, 43210

12/2020 "Updates in Hodgkin and DLBCL", OncLive State of the Science Summit, Columbus, OH, 43210

Regional

01/2019 "ASH 2018 Updates in Lymphomas", ASH review course, Columbus, OH, 43210

01/2020 "ASH 2019 Updates in Lymphomas", ASH review course, Columbus, OH, 43210

Institutional Educational Lectures

09/2012 "Role of anti-PD1 and anti-PD-L1 antibody in cancer", Internal Medicine Residency Educational Lecture, Marshfield Clinic, Marshfield, WI,

09/2014 "Heparin induced thrombocytopenia - updates", Fellow Educational Lecture, Medical College of Wisconsin, Milwaukee, WI

03/2015 "Updates in AML treatment", Fellow Educational Lecture, Medical College of Wisconsin, Milwaukee, WI

09/2015 "Beyond BCR signaling", Fellow Educational Lecture, Medical College of Wisconsin, Milwaukee, WI

04/2016 "DLBCL Biology and Beyond", Fellow Educational Lecture, Medical College of Wisconsin, Milwaukee, WI

08/2016 "Post Autologous Transplant maintenance therapies in B-cell lymphoid malignancies", Fellow Educational Lecture, Medical College of Wisconsin, Milwaukee, WI

01/2017 "Epigenetics in DLBCL", Fellow Educational Lecture, Medical College of Wisconsin, Milwaukee, WI

01/2018 "Non-Hodgkin Lymphomas", Medical Student Educational Lecture, The Ohio State University, Columbus, OH

07/2018 "Aggressive Non-Hodgkin Lymphoma", Internal Medicine Residency Educational Lecture, The Ohio State University, Columbus, OH

08/2018 "Mantle cell Lymphoma", Fellowship Educational Lecture, The Ohio State

	University, Columbus, OH
08/2018	"Follicular Lymphoma", Fellowship Educational Lecture, The Ohio State University, Columbus, OH
01/2019	"Classical Hodgkin Lymphoma", Fellowship Educational Lecture, The Ohio State University, Columbus, OH
01/2019	"Hodgkin Lymphoma – <i>where are we in 2019?</i> " Radiation Oncology Educational Lecture, The Ohio State University, Columbus, OH
09/2019	"Hodgkin Lymphoma – <i>past, present and future</i> ", Fellowship Educational Lecture, The Ohio State University, Columbus, OH
01/2020	"Hodgkin Lymphoma – <i>where are we in 2020?</i> " Radiation Oncology Educational Lecture, The Ohio State University, Columbus, OH
01/2020	"Therapeutic landscape of Non-Hodgkin Lymphoma" Radiation Oncology Educational Lecture, The Ohio State University, Columbus, OH
02/2020	"Non-Hodgkin Lymphomas", Medical Student Educational Lecture, The Ohio State University, Columbus, OH
02/2021	"Non-Hodgkin Lymphomas", Medical Student Educational Lecture, The Ohio State University, Columbus, OH

Media Appearances

OncLive

Dr. Epperla discusses the current treatment of MCL

Published: Wednesday, Oct 18, 2017

<https://www.onclive.com/onclive-tv/dr-epperla-discusses-the-current-treatment-of-mcl>

OncLive

Dr. Epperla on treatment following ibrutinib in MCL

Published: Wednesday, Nov 01, 2017

<https://www.onclive.com/onclive-tv/dr-epperla-on-treatment-following-ibrutinib-in-mcl>

OncLive

Dr. Epperla on CAR T-cell therapy in MCL

Published: Wednesday, Nov 15, 2017

<https://www.onclive.com/onclive-tv/dr-epperla-on-car-tcell-therapy-in-mcl>

OncLive

Dr. Epperla on FDA approval of frontline Obinutuzumab in Follicular Lymphoma

Published: Thursday, Nov 16, 2017

<https://www.onclive.com/onclive-tv/dr-epperla-on-fda-approval-of-frontline-obinutuzumab-in-follicular-lymphoma>

PEER-REVIEWED WORKSHOPS/PRESENTATIONS

Regional

1. **Epperla N**, Chatterjee S. Treatment Profile of De-Addiction Centre in KIMS. **Oral** presentation at IAPSM & IPHA (Indian Association of Preventive & Social Medicine and Indian Public Health Association) State conference, Vishakhapatnam, India. 01/2005
2. Yazigi N, Huang J, **Epperla N**, Yale S. Metastatic Pulmonary Calcification Secondary to Primary Hyperparathyroidism. Poster presentation at American College of Physicians; Wisconsin Dells, WI. 09/2010
3. **Epperla N**, Kasirye Y, Simpson M, Liang H, Mamillapalli C, Yale S. Effect of Hyperglycemia on outcomes in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD). **Oral** presentation at American College of Physicians; Wisconsin Dells, WI. 9/2011
4. Motapothula M, **Epperla N**, Madden K. (2011, September). Reversible Cerebral Vasoconstriction Syndrome (RCVS): "A Great Masquerader of Complex Migraine". Poster presentation at Society of General Internal Medicine; Chicago, IL. 09/2011
5. Motapothula M, **Epperla N**, Pathak R. "Think Deep, Get It Right": Ventricular Tachycardia – A Rare Presentation of Hyperthyroidism. Poster presentation at Society of General Internal Medicine; Chicago, IL. 09/2011
6. Bapani S, **Epperla N**, Motapothula U. (2011, September). "Is Bactrim Notorious"? Bactrim induced Thrombotic Thrombocytopenic Purpura (TTP). Plenary session presentation at the Society of General Internal Medicine; Chicago, IL. 09/2011
7. **Epperla N**, Bapani S, Yale S. "A Great Clinical Paradox": Heparin-Induced Thrombocytopenia (HIT), An Over-diagnosed Yet An Under-recognized Entity. **Oral** presentation at American College of Physicians; Wisconsin Dells, WI. 9/2012
8. **Epperla N**, Hocking W. "Blessing for the Bleeder": Bevacizumab in Hereditary Hemorrhagic Telangiectasia (HHT) –A Novel Therapeutic Approach. Poster presentation: American College of Physicians; Wisconsin Dells, WI. 9/2012
9. Bapani S, **Epperla N**, Yale S. Pyoderma Gangrenosum as the first manifestation of Essential Thrombocythemia. Poster Presentation at American College of Physicians; Wisconsin Dells, WI. 9/2012
10. **Epperla N**, Bapani S, Hocking W. "Think outside the Box": Pulseless Electrical Activity (PEA), a Rare Complication of Heparin-Induced Thrombocytopenia (HIT). Poster presentation at Society of General Internal Medicine; Chicago, IL. 9/2012
11. Bapani S, **Epperla N**, Yale S. An uncommon cause of a common symptom. Plenary Presentation at Society of General Internal Medicine; Chicago, IL. 9/2012
12. **Epperla N**, McKiernan F, Charles V Kenney. Fibrogenesis Imperfecta Ossium (FIO) Like. **Oral** presentation at Wisconsin Bone Club; Oconomowoc, WI. 04/2013
13. **Epperla N**, Kunreddy R, Chyou HP, Yale S. Cardiovascular risk assessment in patients with Subclavian artery Stenosis. Poster presentation at Society of General Internal Medicine; Chicago, IL. 09/2013
14. Jayarangaiah A, Blonsky R, **Epperla N**. An unusual case of DVT: May-Thurner syndrome. Poster presentation at American College of Physicians; Wisconsin Dells, WI. 9/2015
15. Levin A, Arce-Lara C, **Epperla N**. Unconventional therapy in the era of targeted agents: Role of Curcumin in the treatment of pancreatic cancer. Poster presentation at American College of Physicians; Wisconsin Dells, WI. 9/2016

16. Gordon J, **Epperla N**. *Too much of a good thing is not good: A case of cold agglutinin autoimmune hemolytic anemia*. Poster presentation at Clinical and Translational Research (CSCTR) and the Midwestern Section of the American Federation for Medical Research (MWFAMR) at Chicago, IL. 04/2019
17. Gordon J, **Epperla N**. *The devil is in the details: A case of drug induced agranulocytosis*. Poster presentation at Clinical and Translational Research (CSCTR) and the Midwestern Section of the American Federation for Medical Research (MWFAMR) at Chicago, IL. 04/2019

National/ International

1. **Epperla N**, Issa M. Appearances are deceptive: Staphylococcal superinfection of Clavicular Tuberculous Osteomyelitis. Poster presentation at Society of Hospital Medicine; San Diego, CA. 04/2012
2. **Epperla N**, Pathak R. Hypocalcemia secondary to Zoledronate therapy in a patient with Vitamin D deficiency. Poster Presentation at American Association of Clinical Endocrinologists (AACE); Philadelphia, PA. 05/2012
3. **Epperla N**, Hess S, Aston P. "*Early Recognition is the Key to Success*": Voltage-Gated Potassium Channel (VGKC) Mediated Limbic Encephalitis. **Oral** Presentation at the American Medical Association Resident/Fellow Section (AMA-RFS) Research Symposium. Honolulu, Hawaii. 11/2012
4. **Epperla N**, Yale S. "*It's all in the Rash*": The Association of Parvovirus B19 and Type I Cryoglobulinemia. Poster Presentation at Society of General Internal Medicine; Denver, CO. 04/2013
5. **Epperla N**, Yale S. "*Drugs Smarter than the Bugs*": Mirtazapine and Mefloquine therapy for non-AIDS Related Progressive Multifocal Leukoencephalopathy. Poster presentation at Society of General Internal Medicine; Denver, CO. 04/2013
6. **Epperla N**, Kunreddy R, Pathak R. "*Think outside the box*": Panhypophysitis with Masked Diabetes Insipidus unveiled by Glucocorticoid Replenishment. Poster presentation at the American Association of Clinical Endocrinologists (AACE) 22nd Annual Scientific and Clinical Congress in Phoenix, AZ. 05/2013
7. **Epperla N**, Brilliant MH, Vidaillet HJ. "Topical timolol for the treatment of epistaxis in hereditary hemorrhagic telangiectasia associated with bradycardia - A look at CYP2D6". **Oral** presentation at the 10th International Scientific HHT (Hereditary Hemorrhagic Telangiectasia) Conference. Cork, Ireland. 06/2013
8. **Epperla N**, Sabbagh S, Usoltseva N, Reriani M. "*Silo Filler's Disease*": A rare cause of acute respiratory distress syndrome (ARDS)". **Oral** Presentation at Chest Annual Meeting; Chicago, IL. 10/2013
9. Usoltseva N, **Epperla N**. Unprovoked Deep Venous Thrombosis in Young Adult Associated with Membranous Obstruction of Inferior Vena Cava. Poster Presentation at Chest Annual Meeting; Chicago, IL. 10/2013
10. **Epperla N**, Vedre J. Methicillin-Sensitive Staphylococcus Aureus Endocarditis with B/L Parotitis and Endophthalmitis. Poster presentation at the Society of Critical Care Medicine 2014 Annual Congress in San Francisco, CA. 01/2014
11. Sabbagh S, **Epperla N**, Bassi D et al. Parvovirus-induced Lupus Glomerulonephritis. Poster Presentation at National Kidney Foundation, Las Vegas, Nevada. 04/2014
12. Sabbagh S, **Epperla N**, Nwoko R. Retroperitoneal fibrosis causing acute kidney injury without anatomical obstruction. Poster presentation at National Kidney Foundation, Las Vegas, Nevada. 04/2014
13. **Epperla N**, Foy P. Is systemic Bevacizumab economical for select hereditary hemorrhagic telangiectasia cases? A cost estimate. Poster presentation at the 11th International Scientific HHT (Hereditary Hemorrhagic Telangiectasia) Conference. FL, USA. 06/2015

14. **Epperla N**, Shah N, Richardson K, Kapke J, Carrum G, Hari P, Hamadani M, Pingali SR, Karmali R, Fenske TS. Impact of routine surveillance imaging on outcomes in patients with diffuse large B-cell lymphoma (DLBCL) undergoing autologous hematopoietic cell transplantation (auto-HCT). Poster presentation at the 57th ASH Annual Meeting and Exposition. Orlando, FL, USA. 12/2015
15. Kapke J, **Epperla N**, Shah N, Richardson K, Carrum G, Hari P, Hamadani M, Pingali SR, Karmali R, Fenske TS. Impact of Routine Surveillance Imaging on Outcomes in Patients with Classical Hodgkin Lymphoma (cHL) undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT). Poster presentation at the 57th ASH Annual Meeting and Exposition. Orlando, FL, USA. 12/2015
16. Dhakal B, Ramalingam S, Shuff J, **Epperla N**, Rein L, Banerjee A, Siker M, Hosking P, Hari P, D'Souza A, Atallah E, Fenske TS, Erickson B, Hamadani M. Local control of Ocular adnexal lymphoproliferative disorders (OALD): similar outcomes in MALT and non-MALT histologies. Poster presentation at the 57th ASH Annual Meeting and Exposition. Orlando, FL, USA. 12/2015
17. Jayarangaiah A, **Epperla N**. Epstein syndrome. **Oral** presentation at American College of Physicians; Washington DC. 05/2016
18. **Epperla N**, Hamadani M, Ahn KW, Oak E, Cashen AF, Kanate AS, Calzada O, Farmer ZL, Tallarico M, Nabhan C, Costa LJ, Kenkre VP, Ghosh N, Cohen JB, Hari PN, Fenske TS. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory Mantle cell lymphoma. Poster presentation at the ASCO 2016. Chicago, IL, USA. 06/2016
19. Greenwell IB, Staton AD, Lee MJ, Switchenko JM, Maly JJ, Blum KA, Grover NS, Matthews S, Park SI, Gordon MJ, Danilov AV, **Epperla N**, Fenske TS, Hamadani M, Flowers CR, Cohen JB. Association of complex karyotype with inferior progression-free and overall survival in mantle cell lymphoma. Poster presentation at the ASCO 2016. Chicago, IL, USA. 06/2016
20. Calzada O, Switchenko JM, Maly JJ, Blum KA, Grover NS, Matthews S, Park SI, Gordon M, Danilov A, **Epperla N**, Fenske TS, Hamadani M, Flowers CR, Cohen JB. Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. Poster presentation at the ASCO 2016. Chicago, IL, USA. 06/2016.
21. Hoogenboom L, **Epperla N**. A Ray of Hope in Catastrophe. Poster presentation at the American Medical Association Resident/Fellow Section (AMA-RFS) Research Symposium. Orlando, FL, USA. 11/2016.
22. Maddocks KJ, **Epperla N**, Chavez JC, Reddy N, Karmali R, Umyarova E, Costa C, Bachanova V, Glenn M, Calzada O, Xavier A, Zhou Z, Hossain NM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal NV, Evans A, Peker D, Forero-Torres A, Flowers C, Fenske TS, Cohen JB, Hamadani M, Costa LJ. Diffuse Large B-Cell Lymphoma with Primary Treatment Failure: Identification of Ultra-High Risk Patients and Benchmarking for Experimental Therapies. **Oral** presentation at the 58th ASH Annual Meeting and Exposition. San Diego, CA, USA. 12/2016.
23. Costa LJ, Reddy N, Maddocks KJ, **Epperla N**, Karmali R, Bachanova V, Umyarova E, Zhou Z, Glenn M, Chavez JC, Hernandez-Ilizaliturri FJ, Costa C, Hossain NM, Calzada O, Al-Mansour Z, Xavier A, Evans A, Chhabra S, Jaglal MV, Barta SK, Lansigan F, Flowers C, Fenske TS, Cohen JB, Hamadani M. Primary Failure Diffuse Large B-Cell Lymphoma: Early Autologous or Donor Hematopoietic Cell Transplantation Not Effective in Patients with Ultra-High Risk Features. **Oral** presentation at the 58th ASH Annual Meeting and Exposition. San Diego, CA, USA. 12/2016.
24. Staton AD, Greenwell IB, Switchenko JM, Maly JJ, Blum KA, Grover NS, Mathews S, Park SI, Gordon M, Danilov A, **Epperla N**, Fenske TS, Hamadani M, Flowers CR, Cohen JB. Risk Stratification of untreated Mantle

- cell Lymphoma patients using MIPI, Ki67 Proliferative Index, and Cytogenetics. Poster presentation at the 58th ASH Annual Meeting and Exposition. San Diego, CA, USA. 12/2016.
25. **Epperla N**, Ahn KW, DiGilio A, Jagasia M, Armand P, Ahmed S, Devine S, Jaglowski S, Kharfan-Dabaja M, Rezvani A, Smith SM, Sureda A, Fenske TS, Hamadani M. Rituximab (R) versus Non-Rituximab (NR) containing Reduced Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) in B-cell Non-Hodgkin Lymphomas (B-NHL): A CIBMTR Analysis. **Oral** presentation at the 2017 BMT Tandem Meeting. Orlando, FL, USA. 2/2017.
26. **Epperla N**, He F, Kodali D, Kleman A, Hari PN, Pasquini M, D'Souza A, Saber W, Shah NN, Fenske TS, Kanate AS, Bachanova V, Hamadani M. Post-Relapse Survival in Lymphoma Patients (pts) after Experiencing Therapy Failure Following an Allogeneic Hematopoietic Cell Transplantation (alloHCT). **Oral** presentation at the 2017 BMT Tandem Meeting. Orlando, FL, USA. 2/2017.
27. Greenwell IB, Valla K, Caulfield S, Switchenko JM, Staton A, Flowers C, Maly J, Blum KA, Grover N, Mathews S, Park SI, Gordon M, Danilov AV, **Epperla N**, Fenske TS, Hamadani M, Cohen JB. Outcomes in Mantle cell lymphoma for elderly patients undergoing autologous stem cell transplant in CR1. Poster presentation at the 2017 BMT Tandem Meeting. Orlando, FL, USA. 2/2017.
28. **Epperla N**, Hamadani M, Fenske TS, Costa LJ. Incidence and survival trends in Mantle cell lymphoma. Poster presentation at Clinical and Translational Research (CSCTR) and the Midwestern Section of the American Federation for Medical Research (MWAfMR) at Chicago, IL. 04/2017
29. **Epperla N**, Hemauer K, Freidman K, Baumann-Kreuziger L. Post-transplant drug associated thrombotic microangiopathy. Poster presentation at Clinical and Translational Research (CSCTR) and the Midwestern Section of the American Federation for Medical Research (MWAfMR) at Chicago, IL. 04/2017
30. **Epperla N**, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, Umyarova E, Bachanova V, Glenn M, Xavier A, Zhou Z, Hernandez-Ilizaliturri FJ, Barta SK, Lansigan F, Mehta AN, Flowers C, Cohen JB, Fenske TS, Hamadani M, Costa LJ. MYC+ relapsed and refractory diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. Poster presentation at the ASCO 2017. Chicago, IL, USA. 06/2017.
31. **Epperla N**, Kleman A, Karafin M, Foy P. Retreatment vs Maintenance strategy of systemic Bevacizumab for Hereditary Hemorrhagic Telangiectasia: *Which is better?* Poster presentation at the 12th International Scientific HHT (Hereditary Hemorrhagic Telangiectasia) Conference. Dubrovnik, Croatia. 06/2017
32. Ye F, **Epperla N**, Liang H, Chyou P, Dart RA, Mazza J, Idris A, Sakkalaek A, Yale S. Impact of combination therapy on cardiovascular outcomes in patients with symptomatic subclavian artery stenosis. Poster presentation at Basic Cardiovascular Sciences (BCVS) 2017 at Portland, OR. 07/2017
33. Badar T, Hamadani M, Bachanova V, Maddocks KJ, Umyarova E, Chavez JC, **Epperla N**, Chhabra S, Xavier A, Karmali R, Salhab M, Reddy N, Hernandez-Ilizaliturri FJ, Flowers C, Evens AM, Zhou Z, Lansigan F, Barta SK, Cohen JB, Fenske TS, Costa LJ. Efficacy of salvage chemotherapy in diffuse large B-cell lymphoma with primary treatment failure according to putative cell of origin. Poster presentation at the 59th ASH Annual Meeting and Exposition. Atlanta, GA, USA. 12/2017.
34. Greenwell BL, Switchenko JM, Staton AD, Saxe D, Maly JJ, Blum KA, Grover NS, Mathews S, Park SI, Gordon M, Danilov A, **Epperla N**, Fenske TS, Hamadani M, Flowers CR, Cohen JB. Complex Karyotype predicts the prognostic impact of WBC count in untreated mantle cell lymphoma and is associated with shortened survival independent of specific cytogenetic abnormalities. Poster presentation at the 59th ASH Annual Meeting and Exposition. Atlanta, GA, USA. 12/2017.

35. Caulfield S, Schlafer D, Switchenko JM, Greenwell BL, Staton AD, Blum KA, Grover NS, Park SI, Danilov A, **Epperla N**, Fenske TS, Hamadani M, Gordon MJ, Mathews S, Valla K, Flowers CR, Cohen JB. Initial salvage approaches for relapsed/refractory mantle cell lymphoma have comparable response rates, progression-free survival and overall survival. Poster presentation at the 59th ASH Annual Meeting and Exposition. Atlanta, GA, USA. 12/2017.
36. **Epperla N**, Ahn KW, Litovich C, Kharfan-Dabaja MA, Smith SM, Sureda A, Fenske TS, Hamadani M. Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) on the Outcomes of Angioimmunoblastic T-Cell Lymphoma (AITL): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. **Oral** presentation at the 60th ASH Annual Meeting and Exposition. San Diego, CA, USA. 12/2018.
37. **Epperla N**, Anghelina M, Zhao Q, Agyeman A, Blachly JS, Rogers K, Lozanski G, Oakes C, Grever M, Andritsos L. Infection at the Time of Initial Therapy for Hairy Cell Leukemia Is Associated with Inferior Time to Next Treatment. Poster presentation at the 60th ASH Annual Meeting and Exposition. San Diego, CA, USA. 12/2018.
38. **Epperla N**, Pavilack M, Olufade T, Bashyal R, Li J, Yuce H, Andritsos L. Adverse Events Among Patients with Hairy Cell Leukemia Treated with Purine Nucleoside Analogs in the United States. Poster presentation at the 60th ASH Annual Meeting and Exposition. San Diego, CA, USA. 12/2018.
39. **Epperla N**, Hallack A, Costa LJ. Recent Survival Trends in Diffuse Large B-Cell Lymphoma (DLBCL)-*Did We Make Any Progress Beyond Rituximab?* Poster presentation at the 60th ASH Annual Meeting and Exposition. San Diego, CA, USA. 12/2018.
40. Anghelina M, **Epperla N**, Rogers K, Guo L, Zhao Q, Blachly JS, Lucas D, Oakes C, Lozanski G, Grever M, Andritsos L. Down-Regulation of CD25 Antigen in Hairy Cell Leukemia Patients after Treatment. Poster presentation at the 60th ASH Annual Meeting and Exposition. San Diego, CA, USA. 12/2018.
41. Badar T, **Epperla N**, Szabo A, Borson S, Vaughn, J, Geroge G, Shah N, Hamadani M, Cashen A, Fenske T. Trends in Post-Relapse Survival in Classical Hodgkin Lymphoma Patients after Experiencing Therapy Failure Following Autologous Hematopoietic Cell Transplantation. Poster presentation at the 60th ASH Annual Meeting and Exposition. San Diego, CA, USA. 12/2018.
42. Maddocks K, Awan F, Huang Y, Ayyappan S, Baiocchi R, **Epperla N**, Jaglowski S, William B, Blum K, Christian B. Interim results of a phase I study of Obinutuzumab, venetoclax and lenalidomide in relapsed and refractory B-cell non-Hodgkin lymphoma. Poster presentation at the 60th ASH Annual Meeting and Exposition. San Diego, CA, USA. 12/2018.
43. Shanmugasundaram K, Goyal S, Switchenko J, Calzada O, Churnetski MC, Kolla B, Bachanova V, Gerson J, Barta S, Maldonado E, Gordon M, Danilov A, Grover NS, Burkhart M, Karmali R, Sawalha Y, Hill B, Ghosh N, Park SI, **Epperla N**, Bond D, Badar T, Blum KA, Hamadani M, Fenske TS, Malecek M, Kahl BS, Flowers CR, Cohen JB. Intensive Induction Regimens in Mantle Cell Lymphoma Patients who Defer Therapy is not Associated with Improved Progression-free or Overall Survival. Poster presentation at the 60th ASH Annual Meeting and Exposition. San Diego, CA, USA. 12/2018.
44. **Epperla N**, Badar T, Szabo A, Vaughn J, Borson S, Saini N, Patel RD, Shah NN, Hamadani M, Ahmed S, Cashen A, Fenske T. Post-relapse survival in Diffuse Large B-cell Lymphoma patients after experiencing therapy failure following autologous hematopoietic cell transplantation. **Oral** presentation at TCT. Houston, TX, USA. 02/2019.
45. Churnetski MC, Switchenko J, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson JN, Barta SK, Maldonado E, Gordon M, Danilov A, Grover NS, Burkhart M, Karmali R, Sawalha Y, Hill B, Ghosh N,

- Park SI, **Epperla N**, Bond D, Badar T, Blum KA, Hamadani M, Fenske TS, Malecek M, Kahl BS, Flowers CR, Cohen JB. Prognostic variables of progression-free survival in Mantle cell lymphoma after autologous stem cell transplantation. **Oral** presentation at TCT. Houston, TX, USA. 02/2019.
46. **Epperla N**, Pavilack M, Olufade T, Bashyal R, Huang T, Yuce H, Andritsos L. Healthcare Costs and Resource Utilization Associated with Adverse Events among Hairy Cell Leukemia Patients Treated with Purine Nucleoside Analogs. Poster presentation at 2019 NCCN Annual Conference. Orlando, FL, USA. 03/2019.
47. Shaddy S, Zhao W, Tu H, Sisson B, Ren R, Caruthers S, Long S, Ru P, **Epperla N**, Abruzzo L, Maddocks K, Jones D. Distinct and Complementary Patterns of B-cell Growth Pathway Mutations in CD5-negative B-cell Lymphoproliferative disorders. Poster presentation at 2019 AACR Annual Meeting. Atlanta, GA, USA. 03/2019.
48. Maakaron J, Zhao Q, Puto M, Derau VR, Robinson J, Brammer J, Penza S, Baiocchi R, Christian B, Saad A, Wall S, Benson D, Efebera Y, Rosko A, Ayyappan S, Grieselhuber N, Vasu S, Larkin K, **Epperla N**, Devarakonda S, Choe H, Chaudhry M, Blaser B, Blachly J, Bhatnagar B, Alinari L, Mims A, Jaglowski S, William BM. Phase I dose-escalation study of venetoclax plus BEAM followed by autologous stem cell transplant for chemoresistant relapsed/refractory, or high-risk non-Hodgkin's lymphoma: preliminary results. Poster presentation at 2019 ICML Meeting. Lugano, Switzerland. 06/2019.
49. William BM, Abbasi A, Huang Y, Larbi R, Giali R, Yang L, Brammer J, Grantier C, Hoffman C, Ayyappan S, Baiocchi R, **Epperla N**, Christian B, Alinari L, Maddocks K, Chung C. A phase II trial of Brentuximab vedotin and lenalidomide in relapsed and refractory cutaneous and peripheral T-cell lymphomas: preliminary results of a phase II trial. Poster presentation at 2019 ICML Meeting. Lugano, Switzerland. 06/2019.
50. Bond DA, Switchenko J, Maddocks K, Churnetski MC, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson J, Barta S, Hill B, Sawalha Y, Martin P, Maldonado E, Gordon M, Danilov A, Grover NS, Mathews M, Burkhart M, Karmali R, Ghosh N, Park SI, **Epperla N**, Badar T, Guo J, Hamadani M, Fenske TS, Malecek M, Kahl BS, Flowers CR, Blum K, Cohen JB. Outcomes for patients with mantle cell lymphoma experiencing frontline treatment failure: A multicenter retrospective study. Poster presentation at 2019 ICML Meeting. Lugano, Switzerland. 06/2019.
51. Hill BT, Switchenko J, Martin P, Churnetski MC, Sawalha Y, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson J, Barta SK, Maldonado E, Gordon M, Danilov A, Grover NS, Mathews M, Burkhart M, Karmali R, Ghosh N, Park SI, **Epperla N**, Bond DA, Badar T, Blum KA, Guo J, Hamadani M, Fenske TS, Malecek M, Maddocks K, Flowers CR, Kahl BS, Cohen JB. Maintenance rituximab is associated with improved overall survival in mantle cell lymphoma patients responding to induction therapy with bendamustine + rituximab. Poster presentation at 2019 ICML Meeting. Lugano, Switzerland. 06/2019.
52. Evens AM, Danilov AV, Jagadeesh D, Sperling A, Kim S, Wei C, Rector D, Lin Y, Vaca R, Sundaram S, Reddy N, Farooq U, D'Angelo C, Bond DA, Berg S, Churnetski MC, Godara A, Khan N, Choi YK, Yazdy M, Rabinovich E, Varma G, Karmali R, Mian A, Ramdial J, Burkart M, Martin P, Ren A, Chauhan A, Diefenback C, Straker-Edwards A, Klein A, Blum KA, Boughan KM, Smith SE, Haverkos BM, Orellana-Noia VM, Kenkre VP, **Epperla N**, Zayak A, Maliske SM, Naik S, Venugopal P, Feldman TA, Smith SD, Stadnik A, Lossos IS, David KA, Caimi P, Kamdar M, Portell CA, Olszewski AJ, Alderuccio JP. The evaluation and treatment of Burkitt lymphoma in the modern era: Real world outcomes and prognostication across 26 academic centers. **Oral** presentation at 61th ASH Annual Meeting and Exposition. Orlando, FL, USA. 12/2019.
53. Zayac A, Evens AM, Stadnik A, Smith SD, Jagadeesh D, Leslie LA, Wei C, Kim SH, Naik S, Sundaram S, Reddy N, Farooq U, Kenkre VP, **Epperla N**, et al. Outcomes of patients with newly diagnosed Burkitt lymphoma

- and CNS involvement treated in modern era: A multi-institutional real-world analysis. **Oral** presentation at 61th ASH Annual Meeting and Exposition. Orlando, FL, USA. 12/2019.
54. Bond DA, Switchenko JM, Maddocks K, Churnestski M, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson JN, Barta SK, Hill BT, Swalha Y, Martin P, Maldonado E, Gordon M, Danilov A, Grover NS, Mathews S, Burkhart M, Karmali R, Ghosh N, Park SI, **Epperla N**, Badar T, Guo J, Hamadani M, Fenske TS, Malecek M, Kahl BS, Flowers CR, Blum KA, Cohen JB. Outcomes following early relapse in patients with mantle cell lymphoma. **Oral** presentation at 61th ASH Annual Meeting and Exposition. Orlando, FL, USA. 12/2019.
55. Hill BT, Switchenko J, Martin P, Churnestski MC, Sawalha Y, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson J, Barta SK, Maldonado E, Gordon M, Danilov A, Grover NS, Mathews M, Burkhart M, Karmali R, Ghosh N, Park SI, **Epperla N**, Bond DA, Badar T, Blum KA, Guo J, Hamadani M, Fenske TS, Malecek M, Kahl BS, Flowers CR, Cohen JB. Maintenance rituximab is associated with improved overall survival in mantle cell lymphoma patients responding to induction therapy with bendamustine + rituximab. Poster presentation at 61th ASH Annual Meeting and Exposition. Orlando, FL, USA. 12/2019
56. Cohen JB, Switchenko J, Shanmugasundaram K, Goyal S, Calzada O, Churnestski MC, Kolla B, Bachanova V, Gerson J, Barta SK, Gordon M, Danilov A, Grover NS, Mathews M, Burkhart M, Karmali R, Swalha Y, Hill BT, Ghosh N, Park SI, **Epperla N**, Bond DA, Badar T, Blum KA, Hamadani M, Fenske TS, Malecek M, Martin P, Guo J, Flowers CR, Kahl BS. Clinical Trial Participation is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma. Poster presentation at 61th ASH Annual Meeting and Exposition. Orlando, FL, USA. 12/2019
57. Christian B, Huang Y, Ayyappan S, Baiocchi R, Brammer J, **Epperla N**, Jaglowski S, William B, Awan F, Maddocks K, Blum K. Results of a phase I study of obinutuzumab, venetoclax and lenalidomide in relapsed and refractory B-cell non-Hodgkin lymphoma. Poster presentation at 61th ASH Annual Meeting and Exposition. Orlando, FL, USA. 12/2019
58. **Epperla N**, Switchenko J, Shanmugasundaram K, Goyal S, Calzada O, Churnestski MC, Kolla B, Bachanova V, Gerson J, Barta SK, Gordon M, Danilov A, Grover NS, Mathews M, Burkhart M, Karmali R, Swalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Badar T, Blum KA, Hamadani M, Fenske TS, Malecek M, Martin P, Guo J, Kahl BS, Flowers CR, Cohen JB. Short Time to Treatment is associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma. Poster presentation at 61th ASH Annual Meeting and Exposition. Orlando, FL, USA. 12/2019
59. **Epperla N**, Costa LJ, Vaughn J, Hanel W, Saba R, Cashen A, Sarmad R, Badar T, Hamadani M, Liu Y, Barta SK, Caimi P, Sethi TK, Reddy N, Burkhart M, Karmali R, Bellow CM, Chavez JC, Kothari S, Hernandez-Ilizaliturri F, Ballard H, Svoboda J, Emery LP, Lansigan F, Glenn MJ, Churnestski MC, Cohen JB, Sorge C, Xavier AC. Impact of Novel agents on outcomes of patients with classical Hodgkin lymphoma with primary treatment failure. Poster presentation at 61th ASH Annual Meeting and Exposition. Orlando, FL, USA. 12/2019
60. William BM, Huang Y, Johnson A, Brammer JE, Reneau JC, Maakaron J, Larbi R, Grantier C, Hoffman C, Ayyappan A, Baiocchi RA, **Epperla N**, Christian BA, Alinari L, Maddocks KJ, Chung C. Brentuximab vedotin and lenalidomide in relapsed and refractory cutaneous and peripheral T-cell lymphomas; A planned interim analysis of phase II trial. Poster presentation at 61th ASH Annual Meeting and Exposition. Orlando, FL, USA. 12/2019
61. Olszewski AJ, Lossos IS, Stadnik A, Smith SD, Jagadeesh D, Kim SH, Phillips TJ, Naik S, Feldman T, Reddy N, Sundaram S, Maliske S, Kenkre VP, **Epperla N**, Savani M, Portell C, Palmisiano N, Klein AK, Evens AM.

- Outcomes of Burkitt lymphoma managed in academic or community centers; real-world evidence (RWE) from 30 US sites. Poster presentation at the ASCO 2020. Chicago, IL, USA. 06/2020
62. Prieto PG, Rayi A, Alnahhas I, Giglio P, **Epperla N**. Rapidly progressive neuropathies as the sole presentation of Neurolymphomatosis. **Oral** presentation at the 25th Annual meeting of Society for Neuro-Oncology (SNO). Austin, TX, USA. 11/2020.
 63. **Epperla N**, Zhao Q, Chowdhury SM, Moyo T, Shea L, Reddy N, Sheets J, Weiner DW, Geethakumari PR, Kandarpa M, JordanBruno X, Thomas C, Churnetski MC, Hsu A, Maakaron J, Caimi P, Torka P, Bello C, Tan C, David KA, Lindsey K, Greenwell IB, Janakiram M, Olszewski AJ, Cohen JB, Palmisiano N, Umtarova E, Wilcox RA, Awan FT, Barta SK, Grover NS, Bartlett NL, Sawalha Y, Christian BA, Herrera AF, Shouse G. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory marginal zone lymphoma: A multicenter cohort study. Poster presentation at 62th ASH Annual Meeting and Exposition. 12/2020
 64. Vaughn JL, Xavier A, **Epperla N**. Racial and Ethnic Disparities in the Survival of Patients with Indolent Non-Hodgkin Lymphoma in the United States: A Population-Based Analysis. **Oral** presentation at 62th ASH Annual Meeting and Exposition. 12/2020
 65. Vaughn JL, Pinheiro LC, Olszewski A, **Epperla N**. Decreased Lymphoma-Specific Mortality in Patients with Splenic Marginal Zone Lymphoma in the United States. Poster presentation at 62th ASH Annual Meeting and Exposition. 12/2020
 66. Vaughn JL, Pinheiro LC, **Epperla N**. Relative Survival of Patients with Nodal Marginal Zone Lymphoma in the United States: A Population-Based Analysis. Poster presentation at 62th ASH Annual Meeting and Exposition. 12/2020
 67. Vaughn JL, Pinheiro LC, **Epperla N**. Impact of Primary Site and Era of Diagnosis on Mortality in Patients with Extranodal Marginal Zone Lymphoma in the United States: A Population-Based Study. Poster presentation at 62th ASH Annual Meeting and Exposition. 12/2020
 68. Olszewski A, Jakobsen LH, Collins G, Bachanova V, Blum K, Boughan K, Bower M, Cwynarski K, Pria AD, Danilov A, Diefenbach C, **Epperla N**, et al. Burkitt Lymphoma International Prognostic Index (BIPI). **Oral** presentation at 62th ASH Annual Meeting and Exposition. 12/2020
 69. Alderuccio JP, Olszewski AJ, Evens A, Danilov A, Bower M, Jagadeesh D, Zhu C, Sperling A, Kim S, Vaca R, Wei C, Sundaram S, Reddy N, Pria AD, D'Angelo C, Farooq U, Bond D, Berg S, Churnetski MC, Godara A, Khan N, Choi YK, Kassam S, Yazdy M, Rabinovich E, Post F, Varma G, Karmali R, Burkart M, Martin P, Ren A, Chauhan A, Diefenbach C, Straker-Edwards A, Klein A, Blum KA, Boughan KM, Mian A, Haverkos B, Orellana-Noia VM, Kenkre VP, Zayac A, Maliske SM, **Epperla N**, et al. Prognostication, survival and treatment-related outcomes in HIV-associated Burkitt lymphoma: A US and UK collaborative analysis. **Oral** presentation at 62th ASH Annual Meeting and Exposition. 12/2020
 70. David KA, Sundaram S, Kim S, Vaca R, Lin Y, Singer S, Malecek M, Carter J, Zayac A, Kim MS, Reddy N, Habib A, Strouse C, Graber J, Bachanova V, Tsang M, Major A, Bond D, Agrawal P, Mier-Hicks A, Torka P, Rajakumar P, Venugopal P, Glantz M, Goldlust S, Matnani R, Kumar P, Ollila TA, Cai J, Spurgeon S, Sieg A, Cleveland J, **Epperla N**, et al. Real world outcomes and prognostication of older patients with primary central nervous system lymphomas in the contemporary era. **Oral** presentation at 62th ASH Annual Meeting and Exposition. 12/2020
 71. Alderuccio JP, Beaven AW, Shouse G, **Epperla N**, Stefanovic A, Torka P, Castillo JJ, Argnani L, Voorhees T, Alpert A, Chowdhury SM, Reis IM, Zhao M, Edwards D, Martin P, Kamdar M, Herrera AF, Friedberg JW,

- Zinzani PL, Lossos IS. Frontline bendamustine and rituximab in extranodal marginal zone lymphoma. A multicenter analysis. Poster presentation at 62th ASH Annual Meeting and Exposition. 12/2020
72. LaRose MI, Bair SM, Manjunath S, Carter J, Evens AM, Isaac K, Portell CA, Chowdhury SM, **Epperla N**, et al. Radiation-based approached as an alternative to stem cell transplant for relapsed/refractory classical Hodgkin lymphoma: A multicenter retrospective analysis. Poster presentation at 62th ASH Annual Meeting and Exposition. 12/2020.
73. Hanel W, Christian B, Maddocks K, **Epperla N**, William B, Brammer J, Jaglowski S, Bond DA, Sawalha Y, Reneau J, Brammer JE, Baiocchi R, Blum KA, Alinari L. A phase 2 trial of ibrutinib and nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma. Poster presentation at 62th ASH Annual Meeting and Exposition. 12/2020.
74. Agrawal P, David KA, Chen Z, Sundaram S, Kim S, Vaca R, Lin Y, Singer S, Malecek M, Carter J, Zayac A, Kim MS, Reddy N, Habib A, Strouse C, Graber J, Bachanova V, Tsang M, Major A, Bond D, Agrawal P, Mier-Hicks A, Torka P, Rajakumar P, Venugopal P, Glantz M, Goldlust S, Matnani R, Kumar P, Ollila TA, Cai J, Spurgeon S, Sieg A, Cleveland J, **Epperla N**, et al. EBV-positive primary CNS lymphoma in older patients: incidence, characteristics, tumor pathology and outcomes across a large multicenter cohort. Poster presentation at 62th ASH Annual Meeting and Exposition. 12/2020.

BIBLIOGRAPHY

Peer Reviewed Journal Publications/Original Papers

1. Kasirye Y, Manne JR, **Epperla N**, Bapani S, Garcia-Montilla RJ. Apical Hypertrophic Cardiomyopathy presenting as recurrent unexplained syncope. Clin Med Res. 08/2011; 10(1): 26-31.
2. Kasirye Y, Danhof RS, **Epperla N**, Garcia-Montilla RJ. Sweet's syndrome: One disease, Multiple faces. Clin Med Res. 2011 Nov; 9(3-4):134-6.
3. Manne JR, Kasirye Y, **Epperla N**, Garcia-Montilla RJ. Non-Cardiogenic pulmonary edema complicating electroconvulsive therapy: Short review of pathophysiology and diagnostic approach. Clin Med Res. 2012 Aug; 10(3):131-6.
4. Kasirye Y, **Epperla N**, Manne JR, Bapani S, Garcia-Montilla RJ. Brain Abscess Complicating Acute Pneumococcal Meningitis during Etanercept Therapy. Clin Med Res. 2012 Nov; 10(4):230-5.
5. Hebring SJ, Slager SL, **Epperla N**, Mazza JJ, Ye Z, Zhou Z, Achenbach SJ, Vasco DA, Call TG, Rabe KG, Kay NE, Caporaso NE, Lanasa MC, Camp NJ, Strom SS, Goldin LR, Cerhan JR, Brilliant MH, Schrodi SJ. Genetic Evidence of PTPN22 Effects on Chronic Lymphocytic Leukemia. Blood. 2013 Jan 3; 121(1):237-8.
6. Bapani S, **Epperla N**, Kasirye Y, Mercier R, Garcia-Montilla RJ. Thrombotic thrombocytopenic purpura in a patient on Trimethoprim-Sulfamethoxazole and ADAMTS13 deficiency. Clin Med Res. 2013 Jun;11(2):86-90.
7. Wagner BP, **Epperla N**, Medina-Flores R. Diagnostic dilemma: late presentation of amelanotic BRAF-negative metastatic malignant melanoma resembling clear cell sarcoma – case report. Diagn Pathol. 2013 Nov 25;8(1):192.
8. Kasirye Y, Simpson M, Mamillapalli CK, **Epperla N**, Liang H, Yale SH. Association between blood glucose level and outcomes in patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease. WMJ. 2013 Dec;112(6):244-9.

9. **Epperla N**, Brilliant MH, Vidaillet H. Topical timolol for the treatment of epistaxis in hereditary hemorrhagic telangiectasia associated with bradycardia: a look at CYP2D6 metabolizing variants. *BMJ Case Rep.* 2014 Feb 11;2014. PMID 24518395
10. **Epperla N**, McKiernan FE, Kenney CV. Radiographic findings in Waldenström's macroglobulinemia resembling fibrogenesis imperfecta ossium (FIO): A case report. *Skeletal Radiol.* 2014 Mar; 43(3):381-5.
11. **Epperla N**, McKiernan FE. An uncommon cause of acquired osteosclerosis in adults: hepatitis C associated osteosclerosis. *Skeletal Radiol.* 2014 Sep;43(9):1313-8.
12. Jayarangaiah A, Sehgal R, **Epperla N**. Sjögren's syndrome and neuromyelitis optica spectrum disorders (NMOSD)-a case report and review of literature. *BMC Neurol.* 2014 Oct 9;14:200.
13. **Epperla N**, Landeck J, Sabbagh S. Osmotic demyelination syndrome. *WMJ.* 2014 Oct;113(5):197-8.
14. **Epperla N**, Medina-Flores R, Mazza JJ, Yale SH. Mirtazapine and mefloquine therapy for non-AIDS-related progressive multifocal leukoencephalopathy. *WMJ.* 2014 Dec;113(6):242-5.
15. **Epperla N**, Usoltseva N. Unprovoked deep venous thrombosis in a young adult associated with membranous obstruction of inferior vena cava. *BMJ Case Rep.* 2014 Dec 22;2014.
16. **Epperla N**, Hocking W. "Blessing for the Bleeder": Bevacizumab in Hereditary Hemorrhagic Telangiectasia. *Clin Med Res.* 2015 Mar; 13(1):32-5.
17. **Epperla N**, Kattamanchi S, Fritsche TR. Appearances are Deceptive: Staphylococcus Superinfection of Clavicular Tuberculous Osteomyelitis. *Clin Med Res.* 2015 Jun;13(2):85-8.
18. **Epperla N**, Mazza JJ, Yale SH. A Review of Clinical Signs Related to Ecchymosis. *WMJ* 2015 Apr; 114 (2): 61-5.
19. **Epperla N**, Peterson E, Foy P. An unusual occurrence: a case of venous thromboembolism in pregnancy associated with heterotaxy syndrome. *BMC Hematol.* 2015 May 12;15:7.
20. **Epperla N**, George B. An Unusual Combination: KRAS and BRAF Co-mutated Metastatic Colorectal Cancer. *J Gastrointest Cancer.* 2016 Jun;47(2):206-209.
21. **Epperla N**, McKiernan F. Iatrogenic Cushing syndrome and adrenal insufficiency during concomitant therapy with ritonavir and fluticasone. *SpringerPlus.* 2015 Aug; 4:455.
22. **Epperla N**, Pathak R. Hypocalcemia secondary to Zoledronate therapy in a patient with low vitamin D level. *WMJ.* 2015 Aug;114(4);163-6.
23. **Epperla N**, Fenske TS, Hari PN, Hamadani M. Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas. *World J Transplant.* 2015 Sep 24;5(3):81-8.
24. Jayarangaiah A, **Epperla N**. Early recognition is the key to success: pulseless electrical activity (PEA) as a manifestation of heparin-induced anaphylactoid reaction. *BMJ Case Rep.* 2015 Nov 4; 2015. PMID: 26538127.
25. **Epperla N**, Fenske TS, Lazarus H, Hamadani M. Post autologous transplant maintenance therapies in lymphoid malignancies. *Bone Marrow Transplant.* 2015 Nov;50(11):1393-404.
26. **Epperla N**, Hemauer K, Friedman KD, George JN, Foy P. Congenital Thrombotic Thrombocytopenic Purpura related to a Novel Mutation in ADAMTS13 Gene and Management during Pregnancy. *Am J Hematol.* 2016 Jun;91(6):644-6.
27. Strouse C, **Epperla N**. A Rash Diagnosis: Gemcitabine-associated pseudocellulitis. *J Oncol Pharm Pract.* 2017 Mar 23;23(2):157-160.
28. **Epperla N**, Kapke, JT, Karafin M, Friedman KD, Foy P. Effect of Systemic Bevacizumab in Severe Hemorrhagic Telangiectasia (HHT) associated with Bleeding. *Am J Hematol.* 2016 Jun;91(6): E313-4.

29. **Epperla N**, Strouse C, VanSandt AM, Foy P. Difficult to swallow: warm autoimmune hemolytic anemia in a Jehovah's Witness treated with hemoglobin concentrate complicated by achalasia. *Transfusion* 2016 Jul;56(7):1801-6.
30. **Epperla N**, Weissman DE. Chemotherapy: Response and Survival Data #99. *J Palliat Med.* 2016. Sep;19(9):1011.
31. **Epperla N**, Harrington AM, Hemauer K, Shah NN. Extracavitary primary effusion lymphoma with hemophagocytic lymphohistiocytosis. *Am J Hematol.* 2016 Nov;91(11):1161-1164.
32. **Epperla N**, Pasquini M, Pierce K, Drobyski W, Rizzo JD, Horowitz MM, Saber W, Zellner K, Ramirez S, Bartz K, Raj R, Hari P, Hamadani M. Salvage Haploidentical hematopoietic cell transplantation for graft rejection following a prior Haploidentical Allograft. *Bone Marrow Transplant.* 2017 Jan;52(1):147-150.
33. Raj VR, Hari P, Pasquini M, **Epperla N**, D'Souza A, Fenske T, Shaw BE, Rizzo JD, Drobyski W, Hamadani M. Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections. *Bone Marrow Transplant.* 2016 Dec;51(12):1602-1604.
34. **Epperla N**, Olteanu H, Hamadani M. Think outside the box: Acanthamoeba encephalitis following autologous hematopoietic stem cell transplantation. *Br J Haematol.* 2016 Dec;175(5):758.
35. **Epperla N**, Shah N, Hamadani M, Richardson K, Kapke JT, Patel A, Teegavarapu SP, Carrum G, Hari P, Pingali SR, Karmali R, Fenske TS. Impact of routine surveillance imaging on the outcomes of patients with diffuse large B-cell lymphoma following autologous hematopoietic cell transplantation. *Clin Lymphoma Myeloma Leuk.* 2016 Dec;16(12):672-678.
36. Costa LJ, Maddocks KJ, **Epperla N**, Reddy NM, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Chavez JC, Calzada O, Lansigan F, Hossain NM, Barta SK, Zhou Z, Jaglal MV, Chhabra S, Hernandez-Ilizaliturri FJ, Xavier AC, Mehta A, Peker D, Forero-Torres A, Al-Mansour Z, Evans AM, Cohen JB, Flowers CR, Fenske TS, Hamadani M. Diffuse Large B-Cell Lymphoma with Primary Treatment Failure: Ultra-High Risk Patients and Benchmarking for Experimental Therapies. *Am J Hematol.* 2017 Feb;92(2):161-170.
37. Dang G, **Epperla N**, Muppidi V, Sahr N, Pan A, Simpson P, Baumann-Kreuziger L. Medical Management of Pump Thrombosis in Patients with Continuous Flow Left Ventricular Assist Devices: Systematic Review & Meta-analysis. *ASAIO J.* 2016 Dec 13. PMID 27984314
38. **Epperla N**, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS, Calzada O, Cohen JB, Farmer L, Ghosh N, Tallarico M, Nabhan C, Costa LJ, Kenkre VP, Hari PN, Fenske TS. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma – a "real world" study. *Hematol Oncol.* 2017 Dec;35(4):528-535. PMID 28066928
39. Dhakal B, Fenske TS, Ramalingam S, Shuff J, **Epperla N**, Hosking P, Rein L, Banerjee A, Hari P, D'Souza A, Shah N, Siker M, Griepentrog GJ, Harris GJ, Wells TS, Erickson BA, Hamadani M. Local disease control in ocular adnexal lymphoproliferative disorders: comparative outcomes of MALT versus non-MALT histologies. *Clin Lymphoma Myeloma Leuk.* 2017 May;17(5):305-311.
40. **Epperla N**, Hamadani M, Fenske TS, Costa LJ. Incidence and Survival Trends in Mantle Cell Lymphoma. *Br J Haematol.* 2017 Apr 25. doi: 10.1111/bjh.14699. PMID 28444739.
41. **Epperla N**, Pham AQ, Burnette BL, Wiseman GA, Habermann TM, Macon WR, Ansell AM, Inwards DJ, Micallef IN, Johnston PB, Markovic SN, Porrata LF, Colgan JP, Ristow KM, Nowakowski GS, Witzig TE. Risk of Histologic Transformation and Therapy related Myelodysplasia/Acute Myeloid Leukemia in patients receiving Radioimmunotherapy for Follicular Lymphoma. *Br J Haematol.* 2017 May 3. doi: 10.1111/bjh.14688. PMID 28466487.

42. Kapke JT*, **Epperla N***, Shah N, Richardson K, Carrum G, Hari P, Hamadani M, Pingali SR, Karmali R, Fenske TS. Impact of routine surveillance imaging on the outcomes of patients with classical Hodgkin lymphoma following autologous hematopoietic cell transplantation. *Clin Lymphoma Myeloma Leuk*. 2017 Jul;17(7):408-414. *Co-first authors.
43. **Epperla N**, Ye F, Idris A, Sakkalaek A, Liang H, Chyou P, Dart RA, Mazza J, Yale S. Treatment-related cardiovascular outcomes in patients with symptomatic subclavian artery stenosis. *Cureus* 2017 May 19;9(5): e1262. doi:10.7759/cureus.1262. PMID: 28652946.
44. **Epperla N**, Ahn KW, Ahmed S, Jagasia M, DiGilio A, Devine SM, Jaglowski S, Kennedy V, Rezvani AR, Smith SM, Sureda A, Fenske TS, Kharfan-Dabaja MA, Armand P, Hamadani M. Rituximab-containing reduced intensity conditioning improved progression-free survival following allogeneic transplantation in B-cell non-Hodgkin Lymphoma. *J Hematol Oncol*. 2017 Jun 12;10(1):117. PMID: 28606176.
45. **Epperla N**, Hamadani M. Hematopoietic Cell Transplantation for Diffuse Large B-cell and Follicular Lymphoma: Current Controversies and Advances. *Hematol Oncol Stem Cell Ther* 2017 Jun 13. pii: S1658-3876(17)30040-7. PMID: 28633038.
46. **Epperla N**, Hemauer K, Hamadani M, Freidman K, Baumann-Kreuziger L. Impact of treatment and outcomes for patients with post-transplant drug associated thrombotic microangiopathy. *Transfusion*. 2017 Nov;57(11):2775-2781.
47. **Epperla N**, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, Umyarova E, Bachanova V, Glenn M, Xavier A, Zhou Z, Hernandez-Ilizaliturri FJ, Barta SK, Lansigan F, Mehta AN, Flowers C, Cohen JB, Fenske TS, Hamadani M, Costa LJ. MYC+ relapsed and refractory diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. *Cancer*. 2017 Nov 15;123(22):4411-4418.
48. Jerkins JH, Hamadani M, Zook F, **Epperla N**, Shaw BE, Saber W, Rizzo JD, Pasquini M, Chhabra S, Drobyski WR, Hari PN, Shah NN. Alpha-1-antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. *Am J Hematol*. 2017 Oct;92(10): E610-E611.
49. **Epperla N**, Ahn KW, Armand P, Jaglowski S, Ahmed S, Kenkre VP, Savani B, Jagasia M, Shah NN, Fenske TS, Sureda A, Smith SM, Hamadani M. Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. *Biol Blood Marrow Transplant*. 2018 Jan;24(1):78-85.
50. Xavier A, **Epperla N**, Taub J, Costa LJ. Excess mortality among ten-year survivors of classical Hodgkin Lymphoma in adolescents and young adults. *Am J Hematol*. 2018 Feb;93(2):238-245.
51. Shah NN, Szabo A, Huntington SF, **Epperla N**, Reddy N, Ganguly S, Vose J, Obiozor C, Faruqi F, Kovach AE, Costa LJ, Xavier AC, Okal R, Kanate AS, Ghosh N, Kharfan-Dabaja MA, Strelec L, Hamadani M, Fenske TS, Calzada O, Cohen JB, Chavez J, Svoboda J. R-CHOP vs Dose-Adjusted E-EPOCH in Frontline Management of Primary Mediastinal B-cell Lymphoma: A Multi-centre Analysis. *Br J Haematol*. 2018 Feb;180(4):534-544.
52. **Epperla N**, Hamadani M, Ahn KW, He F, Kodali D, Kleman A, Hari PN, Pasquini M, Fenske TS, Craig MD, Kanate AS, Bachanova V. Survival of lymphoma patients experiencing relapse or progression after an allogeneic hematopoietic cell transplantation. 2018 May;24(5):983-988.
53. Greenwell IB, Staton AD, Lee MJ, , Switchenko JM, Saxe D, Maly JJ, Blum KA, Grover NS, Mathews S, Gordon MJ, Danilov AV, **Epperla N**, Fenske TS, Hamadani M, Park SI, Flowers CR, Cohen JB. Complex Karyotype in mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. *Cancer*. 2018 Jun 1;124(11):2306-2315.

54. Denlinger NM, **Epperla N**, William BM. Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib. *Cancer Manag Res*. 2018 Mar 27;10:615-624.
55. Shah NN, Ahn KW, Litovich C, Fenske T, Ahmed S, Battiwalla M, Bejanyan N, Dahi P, Meade JB, Chen A, Ciurea S, Bachanova V, DeFilipp Z, **Epperla N**, Farhadfar N, Herrera A, Haverkos B, Holmberg L, Hossain N, Kharfan-Dabaja M, Kenkre V, Lazarus H, Murthy H, Nishihori T, Rezvani A, D'Souza A, Savani B, Ulrickson M, Waller W, Sureda A, Smith S, Hamadani M. Outcomes of Medicare-age Eligible Patients with NHL Receiving Reduced-Intensity Allogeneic Transplantation. *Blood Adv*. 2018 Apr 24;2(8):933-940.
56. **Epperla N**, Kleman A, Karafin M, Foy P. Re-treatment versus Extended Treatment Strategy of Systemic Bevacizumab in Hereditary Hemorrhagic Telangiectasia: *Which is better?* *Ann Hematol*. 2018 Sep;97(9):1727-1729.
57. Calzada O, Switchenko JM, Maly JJ, Blum KA, Grover NS, Matthews S, Park SI, Gordon M, Danilov A, **Epperla N**, Fenske TS, Hamadani M, Flowers CR, Cohen JB. Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. *Leuk Lymphoma*. 2018 Dec;59(12):2862-2870.
58. Badar T, Hamadani M, Bachanova V, Maddocks KJ, Umyarova E, Chavez JC, **Epperla N**, Chhabra S, Xavier A, Karmali R, Salhab M, Reddy N, Glenn MJ, Hernandez-Ilizaliturri FJ, Flowers C, Evens AM, Zhou Z, Lansigan F, Barta SK, Cohen JB, Fenske TS, Costa LJ. Efficacy of salvage chemotherapy in diffuse large B-cell lymphoma with primary treatment failure according to putative cell of origin. *Leuk Lymphoma*. 2019 Apr;60(4):940-946.
59. Vaughn JL, Zhao Q, **Epperla N**, Puto M, Roddy J, Elder P, Blum W, Klisovic R, Jaglowski S, Penza S, William B, Andritsos L, Brammer JE, Hofmeister C, Efebera Y, Devine S, Cataland S, Vasu S. Transplant-associated thrombotic microangiopathy: Is the treatment more expensive than the disease? *Bone Marrow Transplant*. 2019 Jun;54(6):913-916.
60. Shah NN, Szabo A, Saba R, Strelec A, Kodali D, Vaughn JL, Esan O, Yang DT, Mato AR, Kanate AS, Olteanu H, Hamadani M, Fenske TS, Kenkre VP, Svoboda J, Cashen AF, **Epperla N**. Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen. *Clin Lymphoma Myeloma Leuk*. 2019 Feb;19(2):95-102.
61. **Epperla N**, Ahn KW, Litovich C, Ahmed A, Battiwalla M, Cohen JB, Dahi P, Farhadfar N, Farooq U, Freytes CO, Ghosh N, Haverkos B, Herrera A, Hertzberg M, Hildebrandt G, Inwards D, Kharfan-Dabaja MA, Khimani F, Lazarus H, Lazaryan A, Lekakis L, Murthy H, Nathan S, Nishihori T, Pawarode A, Prestidge T, Ramakrishnan P, Rezvani AR, Romee R, Shah NN, Sureda A, Fenske TS, Hamadani M. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in Angioimmunoblastic T-cell Lymphoma: A CIBMTR analysis. *J Hematol Oncol*. 2019 Jan 10;12(1):6.
62. **Epperla N**, Shana'ah AY, Jones D, Christian BA, Ayyappan S, Maddocks K, Woyach JA. Resistance mechanism for ibrutinib in Marginal zone lymphoma. *Blood Adv*. 2019 Feb 26;3(4):500-502.
63. Guo S, Jiang S, **Epperla N**, Ma Y, Maadooliat M, Ye Z, Olson B, Wang M, Kitchner T, Joyce J, Strenn R, Mazza JJ, Meece JK, Wu W, Jin L, Smith JA, Wang J, Schrodi SJ. A Gene-Based Recessive Diplotype Exome Scan discovers FGF6, a novel Hepcidin-regulating iron metabolism gene. *Blood*. 2019 Apr 25;133(17):1888-1898.
64. **Epperla N**, Badar T, Szabo A, Vaughn JL, Borson S, Saini NY, Patel RD, Shah NN, Hamadani M, Ahmed S, Cashen A, Fenske TF. Post-relapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. *Blood Adv*. 2019 Jun 11;3(11):1661-1669.
65. **Epperla N**, Hamadani M, Reljic T, Kharfan Dabaja M, Savani B, Kumar A. Upfront Autologous Hematopoietic Cell Transplantation Consolidation for Aggressive B-cell Lymphomas in First Remission in the Rituximab Era: A Systematic Review and Meta-Analysis. *Cancer*. 2019 Dec 15;125(24):4417-4425.

66. Badar T, **Epperla N**, Szabo A, Borson S, Vaughn JL, George G, Saini NY, Shah AR, Patel RD, Ahmed S, Shah NN, Cashen A, Hamadani M, Fenske T. Trends in post-relapse survival in classical Hodgkin lymphoma patients after autologous hematopoietic cell transplantation. *Blood Adv.* 2020 Jan 14;4(1):47-54.
67. Sircar A, Chowdhury SM, Hart A, Bell WC, Singh S, Sehgal L, **Epperla N**. Impact and intricacies of bone marrow microenvironment in B-cell lymphomas: *from biology to therapy*. *Int J Mol Sci.* 2020 Jan 30;21(3).
68. Jagadeesh D, Majhail NS, He Y, Ahn KW, Litovich C, Ahmed S, Aljurf M, Bacher U, Badawy SM, Bejanyan N, Cairo M, Cerny J, **Epperla N**, Farhadfar N, Freytes CO, Gale RP, Haverkos B, Hossain N, Inwards D, Kamble RT, Kenkre VP, Lazarus HM, Lazaryan A, Lekakis L, Mei M, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Ramakrishnan Geethakumari P, Savani BN, Yared JA, Fenske TS, Kharfan-Dabaja MA, Sureda A, Hamadani M. Outcomes of rituximab-BEAM vs BEAM conditioning regimen in patients with diffuse large B-cell lymphoma undergoing autologous transplantation. *Cancer.* 2020 Feb 12. doi: 10.1002/cncr.32752.
69. **Epperla N**, Pavilack M, Olufade T, Bashyal R, Li J, Kabadi SM, Yuce H, Andritsos L. Adverse event rates and economic burden associated with purine nucleoside analogs in patients with hairy cell leukemia: A US population-retrospective claims analysis. *Orphanet J Rare Dis.* 2020 Feb 13;15(1):47.
70. Palmer JD, Bhamidipati D, Shukla G, **Epperla N**, Glass J, Kim L, Shi W. Outcomes after Stereotactic Radiosurgery for CNS lymphoma. *J Neurooncol.* 2020 Feb 27. doi: 10.1007/s11060-020-03444-5.
71. **Epperla N**, Li A, Logan A, Fretham C, Chhabra S, Aljurf M, Chee L, Copelan E, Freytes CO, Hematti P, Lazarus HM, Litzow M, Nishori T, Olsson RF, Prestidge T, Saber W, Wirk B, Yared JA, Loren A, Pasquini M. Incidence, risk factors for and outcomes of transplant associated thrombotic microangiopathy. *Br J Haematol.* 2020 Mar 2. doi: 10.1111/bjh.16457.
72. **Epperla N**. What is the optimal reduced-intensity conditioning regimen for classical Hodgkin lymphoma patients undergoing allogeneic transplantation? – *Is there a one to use or avoid*. *Br J Haematol.* 2020 May 9. doi: 10.1111/bjh.16726.
73. Ghosh N, Ahmed S, Ahn KW, Khanal M, Litovich C, Aljurf M, Bacher U, Bredeson C, **Epperla N**, Farhadfar N, Freytes CO, Ganguly S, Haverkos B, Inwards D, Kamble RT, Lazarus HM, Lekakis L, Murthy H, Nishihori T, Ramakrishnan Geethakumari P, Rizzieri DA, Yared JA, Dabaja MK, Sureda A, Hamadani M. Association of reduced-intensity conditioning regimens with overall survival among patients with non-Hodgkin lymphoma undergoing allogeneic transplant. *JAMA Oncol.* 2020 Jun 4. doi: 10.1001/jamaoncol.2020.1278
74. Hanel W, **Epperla N**. Emerging therapies in Mantle cell lymphoma. *J Hematol Oncol.* 2020 Jun 17;13(1):79. doi: 10.1186/s13045-020-00914-1.
75. **Epperla N**, Vaughn J, Othus M, Hallack A, Costa LJ. Recent survival trends in diffuse large B-cell lymphoma – *have we made any progress beyond rituximab?* *Cancer Med.* 2020 Jun 18. doi: 10.1002/cam4.3237.
76. Evens AM, Danilov AV, Jagadeesh D, Sperling A, Kim S, Vaca R, Wei C, Rector D, Lin Y, Sundaram S, Reddy N, Lin Y, Farooq U, D'Angelo C, Bond DA, Berg S, Churnetski MC, Godara A, Khan N, Choi YK, Yazdy M, Rabinovich E, Varma G, Karmali R, Mian A, Savani M, Burkart M, Martin P, Ren A, Chauhan A, Diefenback C, Straker-Edwards A, Klein A, Blum KA, Boughan KM, Smith SE, Haverkos BM, Orellana-Noia VM, Kenkre VP, Zayak A, Ramdial J, Maliske SM, **Epperla N**, Venugopal P, Feldman TA, Smith SD, Stadnik A, David KA, Naik S, Lossos IS, Caimi P, Kamdar M, Palmisiano N, Bachanova V, Portell CA, Phillips T, Olszewski AJ, Alderuccio JP. Burkitt lymphoma in the modern era: Real world outcomes and prognostication across 30 US cancer centers. *Blood.* 2020 Jul 14. doi: 10.1182/blood.2020006926.
77. **Epperla N**, Ahn KW, Khanal M, Litovich C, Ahmed S, Ghosh N, Fenske T, Kharfan-Dabaja MS, Sureda A, Hamadani M. Impact of reduced-intensity conditioning regimens on outcomes in diffuse large B-cell

- lymphoma undergoing allogeneic transplantation. *Biol Blood Marrow Transplant*. 2020 Sep 18:S1083-8791(20)30579-6.
78. Thangavadivel S, Zhao Q, **Epperla N**, Rike L, Badawi M, Bystry D, Phelps MA, Andritsos L, Rogers K, Jones J, Woyach J, Byrd JC, Awan FT. Early intervention with lenalidomide in patients with high-risk chronic lymphocytic leukemia. *Clin Cancer Res*. 2020 Sep 21:clincanres.1280.2020.
79. Vaughn J, Pinheiro LC, Olszewski A, **Epperla N**. Survival of Patients with Marginal Zone Lymphoma in the United States: A Population-Based Cohort Study (2000 to 2017). *Am J Hematol*. 2021 Jan 21. doi: 10.1002/ajh.26103
80. **Epperla N**, Hamadani M. A new target for Hodgkin lymphoma - Camidanlumab Tesirine. *Curr Hematol Malig Rep*. 2021 Jan 25. doi: 10.1007/s11899-021-00604-w
81. Olszewski A, Jakobsen LH, Collins G, Cwynarski K, Bachanova V, Blum K, Boughan K, Bower M, Pria AD, Danilov A, David KA, Diefenbach C, Ellin F, **Epperla N**, et al. Burkitt Lymphoma International Prognostic Index. *J Clin Oncol*. 2021 Jan 27:JCO2003288. doi: 10.1200/JCO.20.03288
82. Zayac A, Evens AM, Danilov A, Smith SD, Jagadeesh D, Leslie LA, Wei C, Kim SH, Naik S, Sundaram S, Reddy N, Farooq U, Kenkre VP, **Epperla N**, et al. Outcomes of Burkitt lymphoma with central nervous involvement: evidence from a large multi-center cohort study. *Haematologica*. 2021 Feb 4. doi: 10.3324/haematol.2020.270876
83. Liu Q, Harris N, **Epperla N**, Andritsos LA. Current and Emerging Therapeutic Options for Hairy cell leukemia variant. *OncoTargets and Therapy*. Feb 2021 (*in press*).
84. Foltz J, Hess BT, Bachanova V, Bartlett N, Berrien-Elliott MM, McClain E, Becker-Hapak M, Foster M, Schappe T, Kahl B, Mehta-Shah N, Cashen A, Marin ND, McDaniels K, Moreno C, Mosior M, Gao F, Griffith OL, Griffith M, Wagner JA, **Epperla N**, Rock AD, Lee JH, Petti AA, Soon-Shiong P, Fehniger TA. Phase 1 trial of the IL-15 receptor agonist N-803 with rituximab for indolent non-Hodgkin lymphoma. *Clin Cancer Res*. Mar 2021 (*in press*).
85. **Epperla N**, Herrera AF. How we incorporate novel agents into the treatment of Hodgkin lymphoma. *Blood*. Mar 2021 (*in press*).

Books, Chapters and Editorials

Book Chapters

1. **Epperla N**, Jayarangaiah A, Fenske TS. Hepatosplenic T-cell Lymphoma. In: *Handbook of Hematologic Malignancies*. Editors: D. A. Sallman et al. Demos Medical Publishers. Published, 2017
2. **Epperla N**, Atallah E. Langerhans cell Histiocytosis and Histiocytic Sarcoma. In: *Handbook of Hematologic Malignancies*. Editors: D. A. Sallman et al. Demos Medical Publishers. Published, 2017.
3. **Epperla N**, Fenske TS. Mantle Cell Lymphoma. In: *Clinical Manual of Blood & Marrow Hematopoietic Cell Transplantation*. Editors: P. Hari and S. Abutalib. Wiley Blackwell Publishers. Published, 2017
4. **Epperla N**, Hashmi H, Hamadani M. Indolent Lymphomas. In: *Clinical Manual of Blood & Marrow Hematopoietic Cell Transplantation*. Editors: P. Hari and S. Abutalib. Wiley Blackwell Publishers. Published, 2017
5. Schneidewend R, **Epperla N**, Friedman K. Thrombotic Thrombocytopenia Purpura and the Hemolytic Uremic Syndrome in Hoffman, *Hematology: Basic Principles and Practice* 7th ed. Editors: R. Hoffman, E. J. Benz, L.E. Silberstein, H. Heslop, J. Weitz and J. Anastasi. Elsevier Publishers. Published, 2017.

6. **Epperla N**, Hamadani M, Horowitz MM. In: Indications for Allogeneic Hematopoietic Cell Transplantation in Adults. Establishing a Hematopoietic Stem Cell Transplantation Unit: A Practical Guide. Editors: E. Gluckman, D. Niederwieser and M Aljurf. Springer Nature. Published, 2017.
7. Hanel W, Talpaz M, **Epperla N**. Cytokines, Interferons and Hematopoietic Growth Factors. In: Holland-Frei Cancer Medicine 10th Edition. John Wiley & Sons Inc. 2021 (*in press*).

Abstracts

1. **Epperla N**, Meltiady I. Appearances are deceptive: staphylococcal superinfection of clavicular tuberculous osteomyelitis. *Journal of Hospital Medicine* 2012; 7 (Suppl 2):292.
2. **Epperla N**, Yale SH. Drugs smarter than Bugs: Mirtazapine and Mefloquine for Non-AIDS related Progressive Multifocal Leukoencephalopathy. *Journal of General Internal Medicine* 2013; 28:S318-S319.
3. **Epperla N**, Yale SH. Association of Parvovirus B-19 and type 1 Cryoglobulinemia. *Journal of General Internal Medicine* 2013; 28:S400.
4. **Epperla N**, Brilliant MH, Vidaillet HJ. Topical timolol for treatment of epistaxis in hereditary hemorrhagic telangiectasia associated with bradycardia - A look at CYP2D6. *Hematology Reports* 2013; 5(s1): 27-28.
5. **Epperla N**, Sabbagh S, Usoltseva N, Reriani M. Silo Filler's Disease: A Rare Cause of Acute Respiratory Distress Syndrome (ARDS). *Chest* 2013; 144:246A.
6. Usoltseva N, **Epperla N**. Unprovoked Deep Venous Thrombosis in Young Adult Associated with Membranous Obstruction of Inferior Vena Cava. *Chest* 2013; 144:976A.
7. **Epperla N**, Vedre J. Methicillin-sensitive Staphylococcus aureus endocarditis with B/L parotitis and endophthalmitis. *Critical Care Medicine* 2013; 41(12): A298-A299.
8. Sabbagh S, **Epperla N**, Nwoko R. Retroperitoneal fibrosis causing acute kidney injury without anatomic obstruction. *American Journal of Kidney Diseases* 2014; 63 (5): A96.
9. Sabbagh S, **Epperla N**, Bassi D, Goldberg J, Nwoko R. Parvovirus induced lupus glomerulonephritis, a case report. *American Journal of Kidney Diseases* 2014; 63 (5): A95.
10. **Epperla N**, Foy P. Is systemic bevacizumab economical for select hereditary hemorrhagic telangiectasia cases? A cost estimate. *Angiogenesis* Sept 2015; DOI 10.1007/s10456-015-9480-7.
11. **Epperla N**, Shah N, Richardson K, Kapke J, Carrum G, Hari P, Hamadani M, Pingali SR, Karmali R, Fenske TS. Impact of routine surveillance imaging on outcomes in patients with diffuse large B-cell lymphoma (DLBCL) undergoing autologous hematopoietic cell transplantation (auto-HCT). *Blood* 2015; 126(23): 4360.
12. Kapke J, **Epperla N**, Shah N, Richardson K, Carrum G, Hari P, Hamadani M, Pingali SR, Karmali R, Fenske TS. Impact of routine surveillance imaging on outcomes in patients with classical Hodgkin lymphoma (cHL) undergoing autologous hematopoietic cell transplantation (auto-HCT). *Blood* 2015; 126(23): 3169.
13. Dhakal B, Ramalingam S, Shuff J, **Epperla N**, Rein L, Banerjee A, Siker M, Hosking P, Hari P, D'Souza A, Atallah E, Fenske TS, Erickson B, Hamadani M. Local control of Ocular adnexal lymphoproliferative disorders (OALD): similar outcomes in MALT and non-MALT histologies. *Blood* Dec 2015, 126(23) 2711.
14. **Epperla N**, Hamadani M, Ahn KW, Oak E, Cashen AF, Kanate AS, Calzada O, Farmer ZL, Tallarico M, Nabhan C, Costa LJ, Kenkre VP, Ghosh N, Cohen JB, Hari PN, Fenske TS. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory Mantle cell lymphoma. *J Clin Oncol* 34, 2016 (suppl; abstr 7544).

15. Calzada O, Switchenko JM, Maly JJ, Blum KA, Grover NS, Matthews S, Park SI, Gordon M, Danilov A, **Epperla N**, Fenske TS, Hamadani M, Flowers CR, Cohen JB. Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. *J Clin Oncol* 34, 2016 (suppl; abstr 7567).
16. Maddocks KJ, **Epperla N**, Chavez JC, Reddy N, Karmali R, Umyarova E, Costa C, Bachanova V, Glenn M, Calzada O, Xavier A, Zhou Z, Hossain NM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal NV, Evans A, Peker D, Forero-Torres A, Flowers C, Fenske TS, Cohen JB, Hamadani M, Costa LJ. Diffuse Large B-Cell Lymphoma with Primary Treatment Failure: Identification of Ultra-High Risk Patients and Benchmarking for Experimental Therapies. *Blood* 2016; 128: 103.
17. Costa LJ, Reddy N, Maddocks KJ, **Epperla N**, Karmali R, Bachanova V, Umyarova E, Zhou Z, Glenn M, Chavez JC, Hernandez-Ilizaliturri FJ, Costa C, Hossain NM, Calzada O, Al-Mansour Z, Xavier A, Evans A, Chhabra S, Jaglal MV, Barta SK, Lansigan F, Flowers C, Fenske TS, Cohen JB, Hamadani M. Primary Failure Diffuse Large B-Cell Lymphoma: Early Autologous or Donor Hematopoietic Cell Transplantation Not Effective in Patients with Ultra-High Risk Features. *Blood* 2016; 128: 513.
18. Staton AD, Greenwell IB, Switchenko JM, Maly JJ, Blum KA, Grover NS, Mathews S, Park SI, Gordon M, Danilov A, **Epperla N**, Fenske TS, Hamadani M, Flowers CR, Cohen JB. Risk Stratification of untreated Mantle cell Lymphoma patients using MIPI, Ki67 Proliferative Index, and Cytogenetics. *Blood* 2016; 126: 1785.
19. **Epperla N**, Fenske TS, Olteanu H, Pruett J, Goff A, Zellner K, Hamadani M, Shah NN. Outcomes of grade 3A follicular lymphoma: Best treated as aggressive or indolent lymphoma? *Blood* 2016; 128: 5328.
20. **Epperla N**, Ahn KW, DiGilio A, Jagasia M, Armand P, Ahmed S, Devine S, Jaglowski S, Kharfan-Dabaja M, Rezvani A, Smith SM, Sureda A, Fenske TS, Hamadani M. Rituximab (R) versus Non-Rituximab (NR) containing Reduced Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in B-cell Non-Hodgkin Lymphomas (B-NHL): A CIBMTR Analysis. *Biol Blood and Marrow Transplantation* 2017; 23: S47-48.
21. **Epperla N**, Kodali D, Kleman A, Hari PN, Pasquini M, D'Souza A, Saber W, Shah NN, Fenske TS, Kanate AS, Hamadani M. Post-Relapse Survival in Lymphoma Patients (pts) after Experiencing Therapy Failure Following an Allogeneic Hematopoietic Cell Transplantation (allo-HCT). *Biol Blood and Marrow Transplantation* 2017; 23: S48.
22. Greenwell IB, Valla K, Caulfield S, Switchenko JM, Staton A, Flowers C, Maly J, Blum KA, Grover N, Mathews S, Park SI, Gordon M, Danilov AV, **Epperla N**, Fenske TS, Hamadani M, Cohen JB. Outcomes in Mantle cell lymphoma for elderly patients undergoing autologous stem cell transplant in CR1. *Biol Blood and Marrow Transplantation* 2017; 23: S265-266.
23. **Epperla N**, Hamadani M, Fenske T, Costa LJ. Incidence and survival trends in Mantle cell lymphoma. *Journal of Investigative Medicine* 65 (4) 807-879.
24. **Epperla N**, Hemauer K, Freidman K, Baumann-Kreuziger L. Post-transplant drug associated thrombotic microangiopathy. *Journal of Investigative Medicine* 65 (4), 842-843.
25. **Epperla N**, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, Umyarova E, Bachanova V, Glenn M, Xavier A, Zhou Z, Hernandez-Ilizaliturri FJ, Barta SK, Lansigan F, Mehta AN, Flowers C, Cohen JB, Fenske TS, Hamadani M, Costa LJ. MYC+ relapsed and refractory diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. *J Clin Oncol* 35, 2017 (suppl; abstr 7541).
26. Greenwell BL, Switchenko JM, Staton AD, Saxe D, Maly JJ, Blum KA, Grover NS, Mathews S, Park SI, Gordon M, Danilov A, **Epperla N**, Fenske TS, Hamadani M, Flowers CR, Cohen JB. Complex Karyotype predicts the

- prognostic impact of WBC count in untreated mantle cell lymphoma and is associated with shortened survival independent of specific cytogenetic abnormalities. *Blood* 2017; 130: 1499.
27. Caulfield S, Schlafer D, Switchenko JM, Greenwell BL, Staton AD, Blum KA, Grover NS, Park SI, Danilov A, **Epperla N**, Fenske TS, Hamadani M, Gordon MJ, Mathews S, Valla K, Flowers CR, Cohen JB. Initial salvage approaches for relapsed/refractory mantle cell lymphoma have comparable response rates, progression-free survival and overall survival. *Blood* 2017; 130: 1505.
 28. Badar T, Hamadani M, Bachanova V, Maddocks KJ, Umyarova E, Chavez JC, **Epperla N**, Chhabra S, Xavier A, Karmali R, Salhab M, Reddy N, Hernandez-Ilizaliturri FJ, Flowers C, Evens AM, Zhou Z, Lansigan F, Barta SK, Cohen JB, Fenske TS, Costa LJ. Efficacy of salvage chemotherapy in diffuse large B-cell lymphoma with primary treatment failure according to putative cell of origin. *Blood* 2017; 130: 4141.
 29. Ye F, **Epperla N**, Liang H, Chyou P, Dart R, Mazza J, Idris A, Sakkalaek A, Yale S. Impact of Combination Therapy on Cardiovascular Outcomes in Patients with Symptomatic Subclavian Artery Stenosis. *Circulation Research*. 2018;121:A219.
 30. **Epperla N**, Ahn KW, Litovich C, Kharfan-Dabaja MA, Smith SM, Sureda A, Fenske TS, Hamadani M. Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) on the Outcomes of Angioimmunoblastic T-Cell Lymphoma (AITL): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. *Blood* 132 (Suppl 1), 969-969.
 31. **Epperla N**, Anghelina M, Zhao Q, Agyeman A, Blachly JS, Rogers K, Lozanski G, Oakes C, Grever M, Andritsos L. Infection at the Time of Initial Therapy for Hairy Cell Leukemia Is Associated with Inferior Time to Next Treatment. *Blood* 132 (Suppl 1), 2305-2305.
 32. Badar T, **Epperla N**, Szabo A, Borson S, Vaughn, J, Geroge G, Shah N, Hamadani M, Cashen A, Fenske T. Trends in Post-Relapse Survival in Classical Hodgkin Lymphoma Patients after Experiencing Therapy Failure Following Autologous Hematopoietic Cell Transplantation. *Blood* 132 (Suppl 1), 2918-2918.
 33. Anghelina M, **Epperla N**, Rogers K, Guo L, Zhao Q, Blachly JS, Lucas D, Oakes C, Lozanski G, Grever M, Andritsos L. Down-Regulation of CD25 Antigen in Hairy Cell Leukemia Patients after Treatment. *Blood* 132 (Suppl 1), 4143-4143.
 34. Shanmugasundaram K, Goyal S, Switchenko J, Calzada O, Churnetski MC, Kolla B, Bachanova V, Gerson J, Barta S, Maldonado E, Gordon M, Danilov A, Grover NS, Burkhart M, Karmali R, Sawalha Y, Hill B, Ghosh N, Park SI, **Epperla N**, Bond D, Badar T, Blum KA, Hamadani M, Fenske TS, Malecek M, Kahl BS, Flowers CR, Cohen JB. Intensive Induction Regimens after Deferring Initial Therapy are not associated with improved Progression-free or Overall Survival in patients with Mantle cell lymphoma (MCL). *Blood* 132 (Suppl 1), 4153-4153.
 35. Maddocks K, Awan F, Huang Y, Ayyappan S, Baiocchi R, **Epperla N**, Jaglowski S, William B, Blum K, Christian B. Preliminary results of a phase I study of Obinutuzumab, venetoclax and lenalidomide in relapsed and refractory B-cell non-Hodgkin lymphoma. *Blood* 132 (Suppl 1), 4185-4185
 36. **Epperla N**, Hallack A, Costa LJ. Recent Survival Trends in Diffuse Large B-Cell Lymphoma (DLBCL)-*Did We Make Any Progress Beyond Rituximab?* *Blood* 132 (Suppl 1), 4828-4828
 37. **Epperla N**, Pavilack M, Olufade T, Bashyal R, Li J, Yuce H, Andritsos L. Adverse Events Among Patients with Hairy Cell Leukemia Treated with Purine Nucleoside Analogs in the United States. *Blood* 132 (Suppl 1), 4833-4833.
 38. **Epperla N**, Badar T, Szabo A, Vaughn J, Borson S, Saini NY, Patel RD, Shah NN, Hamadani M, Ahmed S, Cashen A, Fenske T. Post-relapse survival in Diffuse Large B-cell Lymphoma patients after experiencing

- therapy failure following autologous hematopoietic cell transplantation. *Biol Blood and Marrow Transplantation* 2019; 25 (3): S22.
39. Churnetski MC, Switchenko J, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson JN, Barta SK, Maldonado E, Gordon M, Danilov A, Grover NS, Burkhart M, Karmali R, Sawalha Y, Hill B, Ghosh N, Park SI, **Epperla N**, Bond D, Badar T, Blum KA, Hamadani M, Fenske TS, Malecek M, Kahl BS, Flowers CR, Cohen JB. Prognostic variables of progression-free survival in Mantle cell lymphoma after autologous stem cell transplantation. *Biol Blood and Marrow Transplantation* 2019; 25 (3): S23-S24.
40. **Epperla N**, Pavilack M, Olufade T, Bashyal R, Huang T, Yuce H, Andritsos L. Healthcare Costs and Resource Utilization Associated with Adverse Events among Hairy Cell Leukemia Patients Treated with Purine Nucleoside Analogs. *JNCCN*; 17 (3.5): HSR19-086-HSR19-086.
41. Gordon J, **Epperla N**. Too much of a good thing is not good: A case of cold agglutinin autoimmune hemolytic anemia. *Journal of Investigative Medicine* 67 (5), 889-890.
42. Gordon J, **Epperla N**. The Devil is in the details: A case of drug induced agranulocytosis. *Journal of Investigative Medicine* 67 (5), 891-892.
43. Maakaron J, Zhao Q, Puto M, Derau VR, Robinson J, Brammer J, Penza S, Baiocchi R, Christian B, Saad A, Wall S, Benson D, Efebera Y, Rosko A, Ayyappan S, Grieselhuber N, Vasu S, Larkin K, **Epperla N**, Devarakonda S, Choe H, Chaudhry M, Blaser B, Blachly J, Bhatnagar B, Alinari L, Mims A, Jaglowski S, William BM. Phase I dose-escalation study of venetoclax plus BEAM followed by autologous stem cell transplant for chemoresistant relapsed/refractory, or high-risk non-Hodgkin's lymphoma: preliminary results. *Hematological Oncology* 2019; Volume 37, Issue S2.
44. William BM, Abbasi A, Huang Y, Larbi R, Giali R, Yang L, Brammer J, Grantier C, Hoffman C, Ayyappan S, Baiocchi R, **Epperla N**, Christian B, Alinari L, Maddocks K, Chung C. A phase II trial of Brentuximab vedotin and lenalidomide in relapsed and refractory cutaneous and peripheral T-cell lymphomas: preliminary results of a phase II trial. *Hematological Oncology* 2019; Volume 37, Issue S2.
45. Bond DA, Switchenko J, Maddocks K, Churnetski MC, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson J, Barta S, Hill B, Sawalha Y, Martin P, Maldonado E, Gordon M, Danilov A, Grover NS, Mathews M, Burkhart M, Karmali R, Ghosh N, Park SI, **Epperla N**, Badar T, Guo J, Hamadani M, Fenske TS, Malecek M, Kahl BS, Flowers CR, Blum K, Cohen JB. Outcomes for patients with mantle cell lymphoma experiencing frontline treatment failure: A multicenter retrospective study. *Hematological Oncology* 2019; Volume 37, Issue S2.
46. Hill BT, Switchenko J, Martin P, Churnetski MC, Sawalha Y, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson J, Barta SK, Maldonado E, Gordon M, Danilov A, Grover NS, Mathews M, Burkhart M, Karmali R, Ghosh N, Park SI, **Epperla N**, Bond DA, Badar T, Blum KA, Guo J, Hamadani M, Fenske TS, Malecek M, Maddocks K, Flowers CR, Kahl BS, Cohen JB. Maintenance rituximab is associated with improved overall survival in mantle cell lymphoma patients responding to induction therapy with bendamustine + rituximab. *Hematological Oncology* 2019; Volume 37, Issue S2.
47. Evens AM, Danilov AV, Jagadeesh D, Sperling A, Kim S, Wei C, Rector D, Lin Y, Vaca R, Sundaram S, Reddy N, Farooq U, D'Angelo C, Bond DA, Berg S, Churnetski MC, Godara A, Khan N, Choi YK, Yazdy M, Rabinovich E, Varma G, Karmali R, Mian A, Ramdial J, Burkart M, Martin P, Ren A, Chauhan A, Diefenback C, Straker-Edwards A, Klein A, Blum KA, Boughan KM, Smith SE, Haverkos BM, Orellana-Noia VM, Kenkre VP, **Epperla N**, Zayak A, Maliske SM, Naik S, Venugopal P, Feldman TA, Smith SD, Stadnik A, Lossos IS, David KA, Caimi P,

- Kamdar M, Portell CA, Olszewski AJ, Alderuccio JP. The evaluation and treatment of Burkitt lymphoma in the modern era: Real world outcomes and prognostication across 26 academic centers. *Blood* (2019) 134 (Supplement_1): 397.
48. Zayac A, Evens AM, Stadnik A, Smith SD, Jagadeesh D, Leslie LA, Wei C, Kim SH, Naik S, Sundaram S, Reddy N, Farooq U, Kenkre VP, **Epperla N**, et al. Outcomes of patients with newly diagnosed Burkitt lymphoma and CNS involvement treated in modern era: A multi-institutional real-world analysis. *Blood* (2019) 134 (Supplement_1): 402.
49. Bond DA, Switchenko JM, Maddocks K, Churnetski M, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson JN, Barta SK, Hill BT, Swalha Y, Martin P, Maldonado E, Gordon M, Danilov A, Grover NS, Mathews S, Burkhart M, Karmali R, Ghosh N, Park SI, **Epperla N**, Badar T, Guo J, Hamadani M, Fenske TS, Malecek M, Kahl BS, Flowers CR, Blum KA, Cohen JB. Outcomes following early relapse in patients with mantle cell lymphoma. *Blood* (2019) 134 (Supplement_1): 402.
50. Hill BT, Switchenko J, Martin P, Churnetski MC, Sawalha Y, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson J, Barta SK, Maldonado E, Gordon M, Danilov A, Grover NS, Mathews M, Burkhart M, Karmali R, Ghosh N, Park SI, **Epperla N**, Bond DA, Badar T, Blum KA, Guo J, Hamadani M, Fenske TS, Malecek M, Kahl BS, Flowers CR, Cohen JB. Maintenance rituximab is associated with improved overall survival in mantle cell lymphoma patients responding to induction therapy with bendamustine + rituximab. *Blood* (2019) 134 (Supplement_1): 1525.
51. Cohen JB, Switchenko J, Shanmugasundaram K, Goyal S, Calzada O, Churnetski MC, Kolla B, Bachanova V, Gerson J, Barta SK, Gordon M, Danilov A, Grover NS, Mathews M, Burkhart M, Karmali R, Swalha Y, Hill BT, Ghosh N, Park SI, **Epperla N**, Bond DA, Badar T, Blum KA, Hamadani M, Fenske TS, Malecek M, Martin P, Guo J, Flowers CR, Kahl BS. Clinical Trial Participation is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma. *Blood* (2019) 134 (Supplement_1): 3483.
52. Christian B, Huang Y, Ayyappan S, Baiocchi R, Brammer J, **Epperla N**, Jaglowski S, William B, Awan F, Maddocks K, Blum K. Results of a phase I study of obinutuzumab, venetoclax and lenalidomide in relapsed and refractory B-cell non-Hodgkin lymphoma. *Blood* (2019) 134 (Supplement_1): 4082.
53. **Epperla N**, Switchenko J, Shanmugasundaram K, Goyal S, Calzada O, Churnetski MC, Kolla B, Bachanova V, Gerson J, Barta SK, Gordon M, Danilov A, Grover NS, Mathews M, Burkhart M, Karmali R, Swalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Badar T, Blum KA, Hamadani M, Fenske TS, Malecek M, Martin P, Guo J, Kahl BS, Flowers CR, Cohen JB. Short Time to Treatment is associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma. *Blood* (2019) 134 (Supplement_1): 3997.
54. **Epperla N**, Costa LJ, Vaughn J, Hanel W, Saba R, Cashen A, Sarmad R, Badar T, Hamadani M, Liu Y, Barta SK, Caimi P, Sethi TK, Reddy N, Burkhart M, Karmali R, Bellow CM, Chavez JC, Kothari S, Hernandez-Ilizaliturri F, Ballard H, Svoboda J, Emery LP, Lansigan F, Glenn MJ, Churnetski MC, Cohen JB, Sorge C, Xavier AC. Impact of Novel agents on outcomes of patients with classical Hodgkin lymphoma with primary treatment failure. *Blood* (2019) 134 (Supplement_1): 1554.
55. Romancki J, Switchenko J, Shanmugasundaram K, Goyal S, Calzada O, Churnetski MC, Kolla B, Bachanova V, Gerson J, Barta SK, Gordon M, Danilov A, Grover NS, Mathews M, Burkhart M, Karmali R, Swalha Y, Hill BT, Ghosh N, Park SI, **Epperla N**, Bond DA, Badar T, Blum KA, Hamadani M, Fenske TS, Malecek M, Kahl BS, Martin P, Guo J, Flowers CR, Cohen J. The Impact of Pre-Diagnosis Tobacco use in Mantle Cell Lymphoma. *Blood* (2019) 134 (Supplement_1): 5891.

56. Olszewski AJ, Lossos IS, Stadnik A, Smith SD, Jagadeesh D, Kim SH, Phillips TJ, Naik S, Feldman T, Reddy N, Sundaram S, Maliske S, Kenkre VP, **Epperla N**, Savani M, Portell C, Palmisiano N, Klein AK, Evens AM. Outcomes of Burkitt lymphoma managed in academic or community centers; real-world evidence (RWE) from 30 US sites. *Journal of Clinical Oncology* 38, no. 15_suppl (May 20, 2020) 8043-8043.
57. Prieto PG, Rayi A, Alnahhas I, Giglio P, **Epperla N**. Rapidly progressive neuropathies as the sole presentation of Neurolymphomatosis. *Neuro-Oncology*, Volume 22, Issue Supplement_2, November 2020.
58. **Epperla N**, Zhao Q, Chowdhury SM, Moyo T, Shea L, Reddy N, Sheets J, Weiner DW, Geethakumari PR, Kandarpa M, JordanBruno X, Thomas C, Churnetski MC, Hsu A, Maakaron J, Caimi P, Torka P, Bello C, Tan C, David KA, Lindsey K, Greenwell IB, Janakiram M, Olszewski AJ, Cohen JB, Palmisiano N, Umtarova E, Wilcox RA, Awan FT, Barta SK, Grover NS, Bartlett NL, Sawalha Y, Christian BA, Herrera AF, Shouse G. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory marginal zone lymphoma: A multicenter cohort study. *Blood* (2020) 136 (Supplement 1): 35–36.
59. Vaughn JL, Xavier A, **Epperla N**. Racial and Ethnic Disparities in the Survival of Patients with Indolent Non-Hodgkin Lymphoma in the United States: A Population-Based Analysis. *Blood* (2020) 136 (Supplement 1): 3.
60. Vaughn JL, Pinheiro LC, Olszewski A, **Epperla N**. Decreased Lymphoma-Specific Mortality in Patients with Splenic Marginal Zone Lymphoma in the United States. *Blood* (2020) 136 (Supplement 1): 9.
61. Vaughn JL, Pinheiro LC, **Epperla N**. Relative Survival of Patients with Nodal Marginal Zone Lymphoma in the United States: A Population-Based Analysis. *Blood* (2020) 136 (Supplement 1): 5–6.
62. Vaughn JL, Pinheiro LC, **Epperla N**. Impact of Primary Site and Era of Diagnosis on Mortality in Patients with Extranodal Marginal Zone Lymphoma in the United States: A Population-Based Study. *Blood* (2020) 136 (Supplement 1): 44.
63. Olszewski A, Jakobsen LH, Collins G, Cwynarski K, Bachanova V, Blum K, Boughan K, Bower M, Pria AD, Danilov A, David KA, Diefenbach C, Ellin F, **Epperla N**, et al. Burkitt Lymphoma International Prognostic Index (BL-IPI). *Blood* (2020) 136 (Supplement 1): 46–49.
69. Alderuccio JP, Olszewski AJ, Evens A, Danilov A, Bower M, Jagadeesh D, Zhu C, Sperling A, Kim S, Vaca R, Wei C, Sundaram S, Reddy N, Pria AD, D'Angelo C, Farooq U, Bond D, Berg S, Churnetski MC, Godara A, Khan N, Choi YK, Kassam S, Yazdy M, Rabinovich E, Post F, Varma G, Karmali R, Burkart M, Martin P, Ren A, Chauhan A, Diefenbach C, Straker-Edwards A, Klein A, Blum KA, Boughan KM, Mian A, Haverkos B, Orellana-Noia VM, Kenkre VP, Zayac A, Maliske SM, **Epperla N**, et al. Prognostication, survival and treatment-related outcomes in HIV-associated Burkitt lymphoma: A US and UK collaborative analysis. *Blood* (2020) 136 (Supplement 1): 49–50.
70. David KA, Sundaram S, Kim S, Vaca R, Lin Y, Singer S, Malecek M, Carter J, Zayac A, Kim MS, Reddy N, Habib A, Strouse C, Graber J, Bachanova V, Tsang M, Major A, Bond D, Agrawal P, Mier-Hicks A, Torka P, Rajakumar P, Venugopal P, Glantz M, Goldlust S, Matnani R, Kumar P, Ollila TA, Cai J, Spurgeon S, Sieg A, Cleveland J, **Epperla N**, et al. Real world outcomes and prognostication of older patients with primary central nervous system lymphomas in the contemporary era. *Blood* (2020) 136 (Supplement 1): 24–26.
71. Alderuccio JP, Beaven AW, Shouse G, **Epperla N**, Stefanovic A, Torka P, Castillo JJ, Argnani L, Voorhees T, Alpert A, Chowdhury SM, Reis IM, Zhao M, Edwards D, Martin P, Kamdar M, Herrera AF, Friedberg JW, Zinzani PL, Lossos IS. Frontline bendamustine and rituximab in extranodal marginal zone lymphoma. A multicenter analysis. *Blood* (2020) 136 (Supplement 1): 2–3.

72. LaRose MI, Bair SM, Manjunath S, Carter J, Evens AM, Isaac K, Portell CA, Chowdhury SM, **Epperla N**, et al. Radiation-based approached as an alternative to stem cell transplant for relapsed/refractory classical Hodgkin lymphoma: A multicenter retrospective analysis. *Blood* (2020) 136 (Supplement 1): 31–32.
73. Hanel W, Christian B, Maddocks K, **Epperla N**, William B, Brammer J, Jaglowski S, Bond DA, Sawalha Y, Reneau J, Brammer JE, Baiocchi R, Blum KA, Alinari L. A phase 2 trial of ibrutinib and nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma. *Blood* (2020) 136 (Supplement 1): 29.
74. Agrawal P, David KA, Chen Z, Sundaram S, Kim S, Vaca R, Lin Y, Singer S, Malecek M, Carter J, Zayac A, Kim MS, Reddy N, Habib A, Strouse C, Graber J, Bachanova V, Tsang M, Major A, Bond D, Agrawal P, Mier-Hicks A, Torka P, Rajakumar P, Venugopal P, Glantz M, Goldlust S, Matnani R, Kumar P, Ollila TA, Cai J, Spurgeon S, Sieg A, Cleveland J, **Epperla N**, et al. EBV-positive primary CNS lymphoma in older patients: incidence, characteristics, tumor pathology and outcomes across a large multicenter cohort. *Blood* (2020) 136 (Supplement 1): 4–6.